

# CUMULATIVE INDEX 1996

## Volume 80

January	CANCER SCREENING AND DIAGNOSIS, pages 1-224
March	MANAGED CARE AND OFFICE PRACTICE, pages 225-499
May	OBSTRUCTIVE LUNG DISEASES, PART I, pages 501-675
July	OBSTRUCTIVE LUNG DISEASES, PART II, pages 677-885
September	MANAGEMENT OF CHRONIC LIVER DISEASE, pages 887-1222
November	MANAGEMENT OF THE HIV-INFECTED PATIENT, PART I, pages 1223-1545

Note: Page numbers of article titles are in **boldface** type

- Abdominal pain, in HIV infection, 1397-1398  
 management of, 1400-1401
- Acanthosis nigricans, as dermatologic paraneoplastic syndrome, 182
- Accountability, in managed care, **245-261**  
 for individual physicians, 254-257  
 for organizations of providers, 251-254
- Acetazolamide, for hypoxemia during sleep, in chronic obstructive pulmonary disease, 831
- Acetic acid, glacial, acute exposure to, long-term effects of, 763-764
- Acetohexamide, for non-insulin-dependent diabetes mellitus, 464
- Acquired immunodeficiency syndrome (AIDS), and lung, **775-801**  
 cardiac conditions associated with, 1495  
 classification of, 1286  
 defects in host defenses associated with, 1288  
 definition of, 1232-1234, 1285-1287  
 development of, 1287-1289  
 diarrhea in, causes of, 1404-1408  
 epidemiology of, **1223-1238**  
 age, 1228  
 distribution in United States, 1233  
 gender, 1225-1228  
 geographic trends, 1232  
 global trends, 1234-1235  
 in women, 1225-1228  
 incidence of, 1235  
 molecular, 1235-1236  
 overall morbidity and mortality, 1224  
 prevention of, 1236  
 racial and ethnic minorities, 1228-1229  
 risk behavior, 1229-1232  
 heterosexual transmission, 1231  
 injecting drug use, 1230-1231  
 men having sex with men, 1229-1230  
 incidence of, changes in, 1226, 1235  
 ocular manifestations of, 1472  
 persons reported with, changes in characteristics of, 1227
- Actinic keratosis, skin cancer screening of, 105
- Acute asthma. See under *Asthma*.
- Acyclovir, for HIV infection, 1301
- Adeno-associated virus, liver-directed gene therapy with, 1203-1204
- Adenocarcinoma, colorectal, liver metastases from, 914-915  
 case study of, 921-922  
 in metastases of unknown primary site, chemotherapy trials for, 167  
 recommended evaluation and therapy for, 161  
 treatment of, moderately differentiated, 166-167  
 poorly differentiated, 163-164  
 well-differentiated, 166-167  
 lung, computed tomography of, 207

- Adenoma, hepatic, 909-910
- Adenovirus, liver-directed gene therapy with, 1202-1203
- Adnexal mass, algorithm for, 211
- Adolescence, in children with HIV infection, 1326
- Adrenal insufficiency, in HIV infection, 1454-1455
- Aflatoxin B, and hepatocellular carcinoma, 1124
- African-American patients, cancer screening barriers in, 121
- Age, advanced, as contraindication to liver transplantation, 1075-1076
- and chronic obstructive pulmonary disease, 502
- and lung cancer, 65
- as cancer screening barrier, 122-123
- Agricultural dust exposure, airflow obstruction with, 867
- chronic bronchitis with, 866-867
- AIDS. See *Acquired immunodeficiency syndrome (AIDS)*; *Human immunodeficiency virus (HIV)*.
- AIDS cholangiopathy syndrome, in HIV infection, 1397-1399
- AIDS dementia complex. See *HIV dementia*.
- AIDS-defining conditions, 1286-1287
- AIDS-related complex, 1286-1287
- Air pollution, ambient, and chronic obstructive pulmonary disease, 502, 515-517
- Air trapping, in mechanical ventilatory support of severe acute asthma, 690
- Airflow, chronic limitation of, clinical exercise testing in, 565-587. See also *Exercise testing*.
- diffusing capacity in, 549-564
- effect on carbon monoxide uptake, 556-557
- lung transplantation in, 657-670. See also *Lung transplantation*.
- physiology of, 566-573
- blood gases and gas exchange, 569-570
- cardiac function, 571
- limb muscles, 573
- mechanics, 568-569
- metabolic acidosis, 571-572
- metabolic rate, 572
- respiratory muscle function, 570-571
- symptoms, 572-573
- ventilation and breathing pattern, 566-568
- following lung reduction surgery, in chronic obstructive pulmonary disease, 631
- nasal/oral, as screening for obstructive sleep apnea, 809
- obstruction of, and lung cancer, 647
- chronic, with mineral dust exposure, 852-862
- with organic dust exposure, 862-867
- with agricultural dust exposure, 867
- with coal dust exposure, 853, 858
- with cotton dust exposure, 865-866
- with grain dust exposure, 863-865
- with occupational exposures, community surveys of, 870
- Airway, disease of, occupationally related, identification of, 851-852
- excessive narrowing of, with long-term beta-agonist use, 734
- hyperresponsiveness of, with reactive airways dysfunction syndrome, 757
- obstruction of, effect on arterial oxygen tension, 683
- occupationally induced, 851-878
- with asbestos dust exposure, 861
- with gold dust exposure, 859-860
- with mineral dust exposure, 860-862
- with reactive airways dysfunction syndrome, 757
- responsiveness of, and chronic obstructive pulmonary disease, 502, 505-508
- secretions of, as trigger for increased nocturnal bronchoconstriction, 839
- Airway responsiveness, in lung health study, 541-542
- Alcohol, and hepatocellular carcinoma, 1124
- for hypoxemia during sleep, in chronic obstructive pulmonary disease, 832
- in preconception counseling, 351-352
- Alcohol recidivism, in liver transplant recipient, 1114-1115
- Alcoholic hepatitis, and liver function abnormalities, 894
- cholestatic liver disease vs, 1012
- Alkaline phosphatase, elevated, approach to, 890
- Allergen responsiveness, increased, with long-term beta-agonist use, 736-737
- Allergy, role in chronic obstructive pulmonary disease, 508
- Almitrine, for hypoxemia during sleep, in chronic obstructive pulmonary disease, 830
- Alpha<sub>1</sub>-antitrypsin, deficiency of, and chronic obstructive pulmonary disease, 502, 508-512
- and liver function abnormalities, 895-896
- as indication for liver transplantation, 1089
- chronic obstructive pulmonary disease unrelated to, genetic studies of, 512
- lung transplantation for, 657-670. See also *Lung transplantation*.

- replacement therapy with, after lung transplantation, 667-668
- Alpha-fetoprotein, as testicular cancer marker, 192
- in hepatocellular carcinoma screening and diagnosis, 1125-1126
- Amebic hepatic abscess, 914
- Amenorrhea, primary care physician management of, 328-330
- Aminotransferase, abnormal, evaluation of, 887
- elevated, in pregnancy, differential diagnosis of, 1170
- normal, as variant of hepatitis C, 968-969
- Amphotericin B, for fungal infection, in HIV infection, 1349
- Amplicor monitor test, of hepatitis C virus, 944-945
- Anal disease, screening for, in HIV patient, 378-379
- Anemia, as hematologic paraneoplastic syndrome, 181
- hemolytic, in pregnancy, 1178-1179
- Angiomatosis, bacillary, dermatologic, in HIV infection, 1420
- Antibiotics, for chronic obstructive pulmonary disease, 600-601
- for liver transplant recipient, 1108, 1111
- Anticholinergics, for asthma, 704-705
- severe acute, 686-687
- for chronic obstructive pulmonary disease, 599
- Anticoagulation, outpatient, by primary care physician, 475-491
- prophylactic, 359
- Antidepressant medication, 437-443
- pharmacologic properties and clinical consequences of, 438
- synaptic effect and therapeutic dose range of, 437
- Anti-inflammatory agents, for asthma, 705
- nocturnal, 840
- Antireflux surgery, for gastroesophageal reflux disease, 425
- Antiretroviral therapy, for HIV infection, 383-387, 1263-1282, 1298-1301
- acyclovir, 1300-1301
- agents for, 1263-1274
- inhibitors of viral attachment, 1263-1265
- nucleoside analogue reverse transcriptase inhibitors, 1265-1271
- recommended dosing of, 1265
- combination therapy, 386-387
- didanosine, 385, 1298-1299
- drug resistance, 1300-1301
- early vs delayed initiation, 1300
- in children, 1324-1325
- lamivudine, 386, 1299
- recommendations, 1299
- saquinovir, 1299
- stavudine, 386, 1299
- zalcitabine, 385-386, 1299
- zidovudine, 383-385, 1298-1299
- Antiviral therapy, agents for, inhibitors of viral attachment, 1263-1265
- miscellaneous, under development, 1274
- nonnucleoside reverse transcriptase inhibitors, 1271-1272
- nucleoside analogue reverse transcriptase inhibitors, 1265-1271
- didanosine, 1267-1269
- lamivudine, 1271
- stavudine, 1270-1271
- zalcitabine, 1269-1270
- zidovudine, 1266-1267
- protease inhibitors, 1272-1274
- indinavir, 1273
- ritonavir, 1273
- saquinavir, 1272-1273
- common clinical issues in, 1274-1276
- choice of agents, 1274-1275
- combination therapy, 1275
- follow-up and alteration of therapy, 1275-1276
- initiation of therapy, 1274-1275
- prophylaxis for percutaneous HIV exposure, 1276
- for HIV dementia, 1370
- Apical mass, computed tomography of, 207
- radiography of, 206
- Apnea, sleep, 803-820. See also *Sleep apnea*.
- Arrhythmias, with continuous positive airway pressure, in obstructive sleep apnea, 814
- Arterial blood gas measurements, for severe acute asthma, 681-683
- Arterial embolization, transcatheter, for hepatocellular carcinoma, 1132
- Arterial oxygen tension, effect of airway obstruction on, 683
- Arteriopathy, myocardial, in HIV infection, 1498
- Asbestos dust exposure, chronic bronchitis in, 861
- Ascites, causes of, 1024
- classification of, 1025
- treatment of, 1025-1026
- with portal hypertension, 1023-1026
- Asialoglycoprotein, antibodies to, in autoimmune hepatitis, 976
- Aspergillosis, in HIV infection, 1349-1350
- Asthma, acute, 677-699
- definitions of, 677
- life-threatening, prognosis and prevention of, 695-696

Asthma (*Continued*)

- severe, clinical features of, 679-684
    - investigations, 680-684
      - arterial blood gas measurements, 681-683
      - chest radiography, 684
      - pulmonary function tests, 680-681
    - markers of severity, 681
    - signs, 679-680
    - spirographic data, 682
    - symptoms, 679
    - tempo of illness, 679
  - complications in, 694-695
  - mechanical ventilatory support in, 688-694. See also *Ventilatory support*.
  - medical treatment of, 684-688
    - bronchodilators, 685-687
    - management and monitoring of, 688-689
    - oxygen, 685
    - systemic corticosteroids, 687-688
    - unconventional therapy in, 694
  - symptoms of, 678
  - treatment of, 678
  - and chronic obstructive pulmonary disease, 505
  - and human immunodeficiency virus, 790-791
  - and sleep, 834-841
  - bronchial, control of, beta-agonists for, 720-729
  - effect on carbon monoxide uptake, 556
  - exacerbations in, patient education in, 709-710
  - home monitoring of peak expiratory flow in, patient education in, 710-711
  - in alpha<sub>1</sub>-antitrypsin deficiency, 509-510
  - in preconception counseling, 354-355
  - inducers of, 702-703
  - irritant-induced, and reactive airways dysfunction syndrome, 750-770. See also *Reactive airways dysfunction syndrome*.
  - medications for, patient understanding of, 707-708
  - morbidity of, with regular beta-agonist treatment, 739-742
  - mortality of, with isoprenaline and fenoterol, 739
  - with regular beta-agonist treatment, 739-742
  - with short-acting beta-agonists, 739-742
  - nocturnal, consequences of, 840
  - treatment of, 840-841
  - occupational, chronic persistent, 868-869
  - nonsensitizing causes of, 749-774
    - variants of, 770-771
      - without a latency period, 750-770
    - outpatient management of, 701-718
    - pathophysiology of, 701-703
    - pharmacotherapy of, 703-706, 713-715
      - anti-inflammatory therapies, 705
      - bronchodilators, 703-704
    - potentially fatal, 677-678
    - severe, pathophysiology of, 677-678
    - stages of, 683
    - stimuli of, 702
    - therapy of, 706-715
      - action plan for, 711-712
      - environmental control in, 711-713
      - goals in, 708-709
      - patient education in, 706-711. See also *Patient education*.
    - triggers of, 702-703
    - understanding of, patient education in, 707
      - worsening at night, reasons for, 836-838
- Atelectasis, segmental, in severe acute asthma, 695
- Atherosclerosis, postmenopausal estrogen replacement for, 314
- Atopy, role in chronic obstructive pulmonary disease, 508
- Atovaquone, for *Pneumocystis carinii* pneumonia, 784-785
- Atrial fibrillation, warfarin for, primary care physician management of, 476-477
- Autoantibodies, diagnostic,
  - unconventional, in autoimmune hepatitis, 977-978
- Autoimmune disorders, cholangiopathy, and liver function abnormalities, 900
- hepatitis, subclassification of, 973-975. See also *Hepatitis*.
- in preconception counseling, 363-364
- liver disease, diagnosis and therapy of, 973-994
- Autoimmunity, and heart, in HIV infection, 1497-1498
- Autonomic nervous activity, as trigger for increased nocturnal bronchoconstriction, 838-839
- Axillary nodal metastases, of unknown primary site, treatment of, 162-163
- Azathioprine, for autoimmune hepatitis, 985
  - in liver transplant recipient, 1109
- Azotemia, in HIV infection, 1439
  - postrenal, 1447-1448
  - prerenal, 1445
- Bacterial infections, in HIV infection, dermatologic, 1419-1420

- in children, 1317-1318
- prophylaxis for, 392
- pulmonary, 1344-1346
- Bacterial pneumonia, in AIDS, 786-790.
  - See also under *Pneumonia*.
- Bacterial vaginosis, primary care physician treatment of, 301-302
- Barrett's esophagus, evaluation of, 418
  - with gastroesophageal reflux disease, continuing primary care management of, 424-425
- Basal cell carcinoma, skin cancer screening of, 106
- Beclomethasone, for control of bronchial asthma, studies supporting, 724-725
- Beneficence, as medical ethical principle, 264
- Benign lentigo, skin cancer screening of, 109
- Beta-agonists, controversy concerning, 719-748
  - for asthma, 704
  - severe acute, 685-686
  - long-acting, 738-739, 742
  - long-term use of, adverse effects of, adverse interaction with corticosteroids, 737-738
  - failure to prevent excessive airway narrowing, 734
  - impaired release of inflammation-modifying mediators, 737
  - increased allergen responsiveness, 736-737
  - increased bronchial hyperresponsiveness, 734
  - potential mechanism for, 732-739
  - rebound bronchoconstriction, 732-733
  - stereoisomerism and airway hyperresponsiveness, 734-736
  - tachyphylaxis, 733
  - regular, and asthma morbidity and mortality, 739-742
  - and control of bronchial asthma, 720-729
    - studies supporting, 723-727
    - and lung function, 729-732
    - oral vs, lung function with, 731
- Beta<sub>2</sub>-agonists, for chronic obstructive pulmonary disease, 598-599
- Beta-human chorionic gonadotropin, as testicular cancer marker, 192
- Bethesda system, for Pap smear reporting, 48-49
  - of cervical cytology nomenclature, 305
- Biliary cirrhosis, primary, post-transplantation correlation with cost, 1079
- Biliary obstruction, cholestatic liver disease vs, 1010-1011
- Biliary tract disease, in HIV infection, 1397-1399
- Biochemical disturbances, in severe acute asthma, 695
- Biopsy, in hepatocellular carcinoma screening and diagnosis, 1127
- Bleeding, anticoagulant-related, 483
  - evaluation of, 485-486
  - prevention and management of, 485
  - risk factors for, 484-485
- Blood gases, in chronic airflow limitation, 569-570
- Body position, as screening for obstructive sleep apnea, 808-809
- Bowen's disease, skin cancer screening of, 107-108
- Brain imaging, in children with HIV infection, 1323
- Brain lesions, in HIV infection,
  - management of, algorithm for, 1378
- Breast, lesion of, evaluation of, 22-24
  - mass in, algorithm for, 204
  - evaluation of, 22-24
- Breast cancer, diagnostic radiologic imaging of, 203-204
  - estrogen replacement and, 315
  - lesion evaluation in, 22-24
  - screening for, and lesion evaluation, 15-22
    - guidelines for, 15-19
  - mammography, 15. See also *Mammography*.
  - midlevel providers and, 140-141
  - patient compliance in, 19-20
  - radiologic, 202
  - self-examination, 21-22
  - tumor markers for, 193-195
- Breast diseases, primary care physician management of, 332-333
- Breathing pattern, in chronic airflow limitation, 566-568, 581
- Breathing rate, in chronic airflow limitation, 581
- Breathing sounds, as screening for obstructive sleep apnea, 808
- Brequinar, for autoimmune hepatitis, 990
- Bronchial hyperreactivity, and asthma
  - worsening at night, 836-837
  - and HIV infection, 790-791
  - increased, with long-term beta-agonist use, 734
- Bronchial responsiveness, symptoms vs, in lung health study, 527
- Bronchial wall thickening, in HIV infection, 793
- Bronchiectasis, and HIV infection, 791-793
- Bronchitis, chronic, and HIV infection, 791-792
  - definition of, 501
  - with agricultural dust exposure, 866-867

Bronchitis (*Continued*)

- with asbestos dust exposure, 861
- with coal dust exposure, 852-853
  - smoking and, 854-855
- with cotton dust exposure, 865
- with gold dust exposure, 859
- with grain dust exposure, 863
- with mineral dust exposure, 860-862
  - with occupational exposures, community surveys of, 869-870
- Bronchoalveolar lavage, for *Pneumocystis carinii* pneumonia diagnosis, 782
- Bronchoconstriction, increased, at night,
  - triggers for, 838-839
- rebound, with long-term beta-agonist use, 732-733
- Bronchodilators, for nocturnal asthma, 840-841
  - for severe acute asthma, 685-687
- regular vs intermittent, asthma control with, 721
  - days to exacerbation with, 722
- response to, symptoms vs, in lung health study, 527
- Bronchospasm, endotracheal tube exacerbation of, in mechanical ventilatory support of severe acute asthma, 691
  - triggers of, in asthma, environmental control of, 713
- Budd-Chiari syndrome, pregnancy in, 1183-1184
- Budesonide, for autoimmune hepatitis, 989
  - for control of bronchial asthma, studies supporting, 726
- Bullectomy, in chronic obstructive pulmonary disease, 626
  - patient selection for, 638
- Bullous lung disease, and HIV infection, 792-794
- Bupropion, for depression, 443
- Byssinosis, asthma with, 770
  - with cotton dust exposure, 865

- CA 15-3, as breast cancer marker, 193
- CA 19-9, as pancreatic cancer marker, 191
- CA 242, as pancreatic cancer marker, 191
- CA-125 antigen, for ovarian cancer diagnosis, 55-56
- Cadmium exposure, and chronic obstructive pulmonary disease, 515
- Calcium metabolism, abnormalities of, in HIV infection, 1462
- Cancer, diagnosis of, disclosure of, 145-151
  - accuracy of information, 150
  - anticipating questions, 149
  - complexity of, 149

- cultivating mutual perception, 148
- delivering bad news, 148-149
- empathy in, 149
- maintaining hope, 150
- minimizing isolation, 148
- operational issues, 149-150
- patient defense mechanisms, 149-150
  - responding to immediate discomforts, 149
- responding to information needs, 148-149
  - timing, 149
  - truthfulness, 150
  - what should be said, 147-148
  - who tells patient, 147-148
- knowledge, attitudes, and beliefs about, as cancer screening barriers, 119-120
  - natural history of, 3
  - prevention of, definitions for, 2
  - radiologic imaging in, 201-218. See also *Radiologic imaging*.
  - screening for. See *Cancer screening*.
- Cancer metastases, of unknown primary site, 153-171. See also *Metastases*.
- Cancer screening, 1-14
  - and health maintenance interventions, criteria for, 10
  - and preventive services, implementation of, 12
  - barriers to, 115-133
    - identification of, 115
    - in special populations, 116
    - institutional, 126-129
      - access to care, 126-127
    - patient education and outreach, 128-129
    - patient tracking, 128
    - payment systems, 127-128
    - standardized criteria and procedures, 129
  - patient, 117-123
    - cancer knowledge, attitudes, and beliefs, 119-120
    - economic, 123
    - ethnic, racial, and cultural, 120-122
    - nonadherence to recommendations, 117-119
    - perceived susceptibility, 119
    - physician-patient relationship, 119
    - sociodemographic, 122-123
  - provider, 123-126
    - attitudes and beliefs, 125
    - conflicting guidelines, 125-126
    - economic disincentives, 126
    - inadequate effort, 125
    - inadequate knowledge, 124-125
    - inadequate patient tracking, 126
    - missed opportunities, 124

- subspecialty-based health care, 125-126
- sources of, 116
- bias in, 3-4
- breast, 15-26. See also *Breast cancer*.
- colorectal, 27-43. See also *Colorectal cancer*.
- costs of, 8
- diagnostic tests for, 4-5
- evidence grading in, 10-11
- gynecologic, 45-61. See also *Gynecologic cancer*.
- improved adherence to, recommendations for, 130
- lung cancer, 63-82. See also *Lung cancer*.
- midlevel providers' role in, 135-144. See also *Midlevel providers*.
- objectives of, 9
- patient preference in, 8-9
- prevention and, 2-9
- prostate cancer, 83-98. See also *Prostate cancer*.
- rationale for, 2-3
- reliability of, 7
- resources for, 12-13
- risk reduction in, 9-10
- risks of, 7-8
- sensitivity in, 5
- skin cancer, 99-114. See also *Skin cancer*.
- specificity in, 5
- strategy for, predictive value of, 5-6
- successful, patient steps to, 118
- systems of, 11-12
- two-by-two table for, 4
- Cancer-associated serum antigen, as ovarian cancer marker, 195
- Candidiasis, in HIV infection,
  - dermatologic, 1420-1421
  - esophageal, 1395-1397
  - vaginal, primary care physician treatment of, 300-301
- Carbon monoxide uptake, as measure of diffusing capacity, 550-555
  - conventional single breath method, 551-552
  - pitfalls of, 553-555
  - intrabreath (exhaled) method, 551
  - pathologic conditions and, 555-558
  - rebreathing method, 550-551
  - steady-state method, 550
  - three-equation method, 552-553
- Carcinoembryonic antigen, as tumor marker, for breast cancer, 194
  - for colorectal cancer, 187
  - for pancreatic cancer, 191
- Carcinoma, poorly differentiated, in metastases of unknown primary site, recommended evaluation and therapy for, 161
  - treatment of, 163-164
- Cardiac disease, in preconception counseling, 361-363
- Cardiac function, in chronic airflow limitation, 571
- Cardiac involvement, in HIV infection, 1493-1512
  - cardiomegaly, 1500-1502
  - cardiomyopathy, 1500-1502
  - endocardial disease, 1503-1504
  - myocardial disease, 1494-1500
  - autoimmunity and the heart, 1497-1498
  - bacterial, fungal, and protozoan opportunistic infections, 1494-1496
  - drug-induced, 1498-1499
  - lymphocytic myocarditis, 1497
  - noninflammatory necrosis, 1498
  - nutritional deficiency, 1499-1500
  - vascular lesions, 1498
  - viral myocarditis, 1496
  - neoplasms, 1502-1503
  - pericardial disease, 1504
  - therapeutic implication, 1504-1505
- Cardiomegaly, in HIV infection, 1500-1502
- Cardiomyopathy, in HIV infection, 1500-1502
- Cardiovascular disease, postmenopausal estrogen replacement for, 314
- Cardiovascular function, in lung reduction surgery, in chronic obstructive pulmonary disease, 633-634
  - in obstructive sleep apnea, effect of continuous positive airway pressure on, 814-815
- Cavernous hemangioma, hepatic, 907-909
  - case study of, 920-921
- CD4+ lymphocytes, decline in, and opportunistic pulmonary infections, 1339
- Central nervous system. See under *Nervous system*.
- Centrum semiovale, multinucleated giant cells in, in HIV infection, 1368
- Cerebellar degeneration, as paraneoplastic neurologic syndrome, 177-178
- Cervical cancer, 45-51
  - biology of, 46
  - cause of, 46
  - diagnosis of, 46-50
    - screening recommendations for, 50-51
    - technique of, 46-47
  - epidemiology of, 45-46
  - screening for, midlevel providers and, 139
- Cervical cytology, clinical management of, 306
  - nomenclature systems for, 305-307
- Cervical disease, screening for, in HIV patient, 377-378



- Cervical lymph nodes, in metastases of unknown primary site, 165
- Cesarean section, rates of, 255
- Chemicals, and asthma, environmental control of, 713
- reproductive effects of, information resources for, 373
- Chemoembolization, for hepatocellular carcinoma, 1132
- Chemotherapy, adjuvant, with liver transplantation, for liver malignancy, 1087
- for hepatocellular carcinoma, 1131
- Chest radiography, for lung cancer detection, 67-69
- for severe acute asthma, 684
- Children, HIV infection in, 1309-1336
- antiretroviral therapy for, 1324-1325
- CDC revised classification system for, 1316-1317
- clinical conditions in, classification systems for, 1314
- complications in, 1313-1320
- diarrhea, 1319
- growth and endocrine dysfunction, 1319-1320
- lymphocytic interstitial pneumonitis, 1348
- Mycobacterium avium intracellulare* complex, 1319
- Pneumocystis carinii* pneumonia, 1315
- respiratory illnesses, 1317
- serious bacterial infections, 1317-1318
- definition of, 1312-1313
- epidemiology of, 1310
- hematologic manifestations, 1320
- natural history of, 1313-1314
- neurologic involvement, 1320-1324
- central nervous system, clinical manifestations, 1321-1322
- treatment of, 1323-1324
- cerebrovascular disease, 1322
- diagnosis of, 1322-1323
- functional brain imaging and spectroscopy, 1323
- neuromuscular system, 1322
- neuropathogenesis, 1321
- neuropathology, 1321
- perinatal transmission of, 1310-1312
- primary care issues in, 1325-1326
- severity of, 1315
- T lymphocyte categories in, 1315
- Chlorambucil, for peritoneal carcinomatosis in women, 160
- Chlorine, acute exposure to, clinical and functional features after, 760
- long-term effects of, 764-765
- reactive airways dysfunction syndrome following, 762-763, 768-769
- Chlorine dioxide, exposure to, reactive airways dysfunction syndrome in, 765, 768-769
- Chlorpropamide, for non-insulin-dependent diabetes mellitus, 464
- Cholangiocarcinoma, intrahepatic, 919
- Cholangiopathy, autoimmune, and liver function abnormalities, 900
- Cholecystitis, acalculous, in HIV infection, 1397
- Cholestasis, benign familial recurrent, cholestatic liver disease vs, 1009
- biochemical abnormalities in, 888
- drug-induced, cholestatic liver disease vs, 1009-1010
- intrahepatic, of pregnancy, 1171-1174
- syndromes of, differential diagnosis of, 899
- Cholestatic injury, and liver function abnormalities, 898-900
- Cholestatic liver disease, diagnosis and therapy of, 995-1019. See also under *Liver disease*.
- Chorioretinitis, fungal, in HIV infection, 1482
- Choroiditis, in HIV infection, 1482-1483
- Chronic obstructive pulmonary disease (COPD). See also *Emphysema*.
- airway responsiveness and, 502, 505-508
- alpha<sub>1</sub>-antitrypsin deficiency and, 502, 508-512
- ambient air pollution and, 502, 515-517
- cigarette smoking and, 501-505, 509
- components of breathing in, 594
- definition of, 501
- diet and, 502, 518
- Dutch hypothesis of, 507
- early intervention in, 523-547. See also *Lung health study*.
- behavioral program for, 525
- objectives of, 524
- smoking intervention program, 530-535
- study design for, 523-526
- study population characteristics, 526-530
- effect on sleep, 825-834
- hypoxemia, oxygen therapy for, 829-830
- pathogenesis of, 826-828
- prediction of, 825-826
- flow-volume curve in, 590
- genetic factors and, 502, 508-512
- home oxygen therapy for, 593-598
- administration devices, 596-598
- and exercise endurance, 595
- delivery systems, 596



- effects of, 594-596
- in city dwellers, chances of, 869
- lung cancer and, 645-655. See also *Lung cancer*.
- lung reduction surgery in, 623-643. See also *Lung reduction surgery*.
- lung transplantation in, 657-670. See also *Lung transplantation*.
- occupational exposures and, 514-515
- overnight oxygen saturation and hypnogram tracings in, 835
- passive smoking exposure and, 502, 517-518
- pathophysiologic effects of, 590-593
  - control of ventilation, 592
  - flow limitation, 590-591
  - hyperinflation, 591-592
  - respiratory muscles, 592-593
- pharmacotherapy for, 598-601
  - antibiotics, 600-601
  - anticholinergic therapy, 599
  - beta<sub>2</sub>-agonists, 598-599
  - corticosteroids, 600
  - theophylline therapy, 599-600
- progressive, respiratory rate changes in, 592-593
- pulmonary rehabilitation for, 601-604
  - education, 603
  - effect on health care use, 601
  - lower extremity exercise, 601-602
  - psychological support, 603
  - upper extremity exercise, 602-603
- respiratory infections and, 512-514
- risk factors for, 501-522
  - environmental, 512-518
- treatment of, 589-609
- unrelated to alpha<sub>1</sub>-antitrypsin deficiency, genetic studies of, 512
- Cigarette smoking, and chronic obstructive pulmonary disease, 501-505
  - in alpha<sub>1</sub>-antitrypsin deficiency, 509
- CIN system, of cervical cytology nomenclature, 305
- Circadian rhythms, and asthma worsening at night, 837
- Cirrhosis, and hepatocellular carcinoma, 1121-1122
  - as indication for liver transplantation, 1082-1083
- biliary, primary, 995-1002
  - and liver function abnormalities, 899-900
  - case study of, 922-923
  - clinical features of, 998
  - complications of, 1001-1002
  - diagnosis of, 999
  - diseases associated with, 999
  - epidemiology and genetics of, 996
  - histologic staging of, 997
  - liver transplantation for, 1000-1001
  - natural history and prognosis of, 1002
  - pathogenesis of, 996-997
  - pathology of, 997-998
  - post-transplantation correlation with cost, 1079
  - treatment of, 999-1001
- decompensated, interferon therapy in, 962
- nonvariceal bleeding in, 1053-1057
  - gastric antral vascular ectasia, 1053-1054
  - hemobilia, 1056
  - Mallory-Weiss tear, 1054-1055
  - peptic ulcer disease, 1055-1056
  - portal hypertensive gastropathy, 1054
  - tumors, 1057
- principal causes of, 1022
- severity of, classification of, 1022
- Cisplatin, for peritoneal carcinomatosis in women, 160
- Clindamycin, for toxoplasmosis encephalitis, in HIV infection, 1377
- Clindamycin-primaquine, for *Pneumocystis carinii* pneumonia, 784
- Clinical exercise testing, in chronic airflow limitation, 565-587. See also *Exercise testing*.
- Coagulation disorders, as hematologic paraneoplastic syndrome, 181
- Coal dust exposure, airflow obstruction in, 853, 858
  - and chronic obstructive pulmonary disease, 515
  - chronic bronchitis in, 852-853
  - smoking and, 854-855
  - forced expiratory volume in, smoking and, 856-857
  - studies of, 852-858
- Coccidioidomycosis, in HIV infection, 1349, 1423
- Colonoscopy, for occult blood in stool, 37-38
- Colorectal adenocarcinoma, liver metastases from, 914-915
  - case study of, 921-922
- Colorectal cancer, algorithm for, 208
  - diagnostic radiologic imaging of, 207-209
  - risk for, 28
  - screening for, 27-43
    - compliance with, 38
    - cost of, 39
    - midlevel providers and, 141-142
    - objective of, 27
    - protocol for, 39
    - radiologic, 202
    - recommendations for, 28-29
    - tests for, 29-38
      - digital rectal examination, 29

- Colorectal cancer (*Continued*)  
 stool occult blood test, 29-35. See also under *Stool*.  
 tumor markers for, 186-188
- Colposcopy, following Pap smear, 50
- Computed tomography scans, in diagnosis of metastases of unknown primary site, 158
- Computers, and medicine, 287-296  
 electronic medical records, 290-294  
   health maintenance and flow sheets, 293-294  
   medications, 292-293  
   problem list, 291  
   procedure note, 293  
   progress note, 291-292  
 practice management systems, 288-290  
   electronic data transmission, 290  
   electronic scheduling, 289  
   hardware for, 289  
   single-site vs multisite practice, 288-289  
   software company stability, 289-290  
 services of, 294-296  
   diagnostic support, 295  
   electronic communication, 295-296  
   telephone, 294-295
- Condoms, in contraception by primary care physician, 307-310
- Condylomata acuminata, primary care physician management of, 324
- Confidentiality, in managed care, ethical conflict in, 271
- Conflicts of interest, in managed care, 272
- Congestive heart failure, warfarin for, primary care physician management of, 479
- Conjunctiva, Kaposi's sarcoma of, in HIV infection, 1483-1484
- Continuous positive airway pressure, during sleep, for cystic fibrosis, 824  
 for hypoxemia during sleep, in chronic obstructive pulmonary disease, 833  
 for obstructive sleep apnea, 813  
   effect on cardiovascular function, 814-815  
   effect on neuropsychologic function, 815-816  
   effect on pulmonary function, 816
- Contraception, by primary care physician, 307-313  
 choice of, 308-309  
 condoms and spermicides, 307-310  
 diaphragm, 310  
 intrauterine device, 310  
 levonorgestrel, 313  
 medroxyprogesterone acetate, 312  
 oral contraceptive pills, 310-312  
 sterilization, 313
- Conventional single breath method, for diffusing capacity measurement, 551-552  
 pitfalls of, 553-555
- Coronary artery disease, warfarin for, primary care physician management of, 478-479
- Corticosteroids, adverse interaction with, with long-term beta-agonist use, 737-738  
 for chronic obstructive pulmonary disease, 600  
 for *Pneumocystis carinii* pneumonia, 1344  
 in liver transplant recipient, 1108  
 inhaled, for asthma, 705, 714  
 systemic, for severe acute asthma, 687-688
- Cotton dust exposure, effects of, 865-866
- Cryoglobulinemia, as variant of chronic hepatitis C, 968-969
- Cryptococcal infections, in HIV infection, 1348-1349, 1422
- Cryptomeningitis, in HIV infection, 1366
- Cryptosporidiosis, and diarrhea, in HIV infection, 1405
- Cultural barriers, in cancer screening, 120-122
- Cushing's syndrome, ectopic, as paraneoplastic endocrine syndrome, 174-175
- Cyanoacrylate, for variceal bleeding, 1048
- Cyclophosphamide, for peritoneal carcinomatosis in women, 160
- Cyclosporiasis, and diarrhea, in HIV infection, 1406
- Cyclosporine, for autoimmune hepatitis, 989  
 in liver transplant recipient, 1108
- Cystic fibrosis, cholestatic liver disease vs, 1012  
 effect on carbon monoxide uptake, 556  
 effect on sleep, 822-825  
 management during sleep, 823-825
- Cytomegalovirus, in HIV infection, central nervous system, 1380-1382  
 dermatologic, 1418  
 encephalitis, 1366  
 esophagitis, 1396  
 prophylaxis for, 395, 1296-1297  
 retinitis, 1473-1580
- Cytomegalovirus hepatitis, pregnancy in, 1183
- Dapsone, for *Pneumocystis carinii* pneumonia, 783-784  
 in HIV patient, 390  
 prophylaxis, 1295-1296
- Demodicidosis infestations, dermatologic, in HIV infection, 1424

- Demographic determinants, in managed care, 267
- Demyelinating polyneuropathy, acute inflammatory, as paraneoplastic neurologic syndrome, 179
- Dental appliances, for obstructive sleep apnea, 812
- Depression, 431-455  
 and suicide, 448-449  
 diagnosis of, 432-435  
 differential diagnosis of, 435-436  
 drugs that precipitate, 435  
 DSM-IV criteria for, 434  
 follow-up and maintenance in, 447-448  
 in elderly, 436  
 in liver transplant recipient, 1115-1116  
 medical conditions mimicking, 435  
 patient referral in, 446-447  
 recurrence of, 449-450  
 risk factors for, 433  
 subtypes of, 431  
 treatment of, 432-447  
   antidepressant medication, 437-443  
     bupropion, 443  
     monoamine oxidase inhibitors, 441-442  
     nefazodone, 442  
     selective serotonin reuptake inhibitors, 441  
     trazodone, 442  
     tricyclic antidepressants, 439-441  
     venlafaxine, 442-443  
   combined pharmacotherapy and psychotherapy, 446  
   nonpharmacologic approaches to, 443-446
- Dermatitis, in HIV infection, eczematous, 1427  
 seborrheic, 1424-1425
- Dermatologic complications, of HIV infection, 1415-1435  
 bacterial infections, 1419-1420  
 fungal infections, 1420-1423  
 infestations, 1423-1424  
 inflammatory disorders, 1428-1429  
 neoplasms, 1429-1431  
 papulosquamous disease, 1424-1428  
 viral disease, 1416-1419
- Dermatologic paraneoplastic syndrome, 181-183
- Dermatomyositis, as paraneoplastic neurologic syndrome, 180
- Dermatophyte infections, dermatologic, in HIV infection, 1421-1422
- Devascularization, for hepatocellular carcinoma, 1131
- Diabetes mellitus, 457-474  
 complications of, detection and intervention in, 466-470  
 macrovascular disease, 469-470  
 nephropathy, 467-468  
 neuropathy, 468-469  
 retinopathy, 466-467  
 criteria for, 460  
 diagnosis of, algorithm for, 461  
   for complication prevention, 459-462  
 glycemic control in, for complication prevention, 463-466  
 in liver transplant recipient, 1113  
 in preconception counseling, 356-357  
 non-insulin-dependent, glucose control in, 458-459, 464  
 screening for, 459-462  
   how to screen, 460-462  
   who to screen, 460
- Diabetes performance report, 257
- Diabetic macrovascular disease, detection and intervention in, 469-470
- Diabetic nephropathy, detection and intervention in, 467-468
- Diabetic neuropathy, detection and intervention in, 468-469
- Diabetic retinopathy, detection and intervention in, 466-467
- Diaphragm, for contraception by primary care physician, 310
- Diarrhea, in HIV infection, 1403-1408  
 causes of, bacterial, 1404  
   cryptosporidiosis, 1405  
   cyclosporiasis, 1406  
   idiopathic, 1407-1408  
   isosporiasis, 1406  
   microsporidiosis, 1406-1407  
   parasitic, 1405  
   viral, 1404-1405
- Didanosine, for HIV infection, 385, 1267-1269, 1298-1299  
 in children, 1324  
 recommended dosing of, 1265
- Diet, and chronic obstructive pulmonary disease, 502, 518
- Diffusing capacity, definition and measurement of, 550-553  
 conventional single breath method, 551-552  
 pitfalls of, 553-555  
 intrabreath (exhaled) method, 551  
 rebreathing method, 550-551  
 steady-state method, 550  
 three-equation method, 552-553  
 in chronic airflow limitation, 549-564
- Digital rectal examination, for colorectal cancer screening, 29  
 for prostate cancer screening, 86-88
- Disease prevalence, and predictive value, 5-6
- Down syndrome, maternal age and, 339
- Doxorubicin, for peritoneal carcinomatosis in women, 160
- Drug(s), and preconception counseling, 352

- Drug(s) (*Continued*)  
 reproductive effects of, information resources for, 373
- Drug hypersensitivity reactions, dermatologic, in HIV infection, 1428-1429
- Drug interactions, in liver transplant recipient, 1112, 1116
- Dual agency, of managed care providers, 266  
 centrality of, 268-269  
 ethical conflict in, 272
- Ductopenia, idiopathic adulthood, cholestatic liver disease vs, 1012
- Duodenal varices, in chronic liver disease, 1040-1041
- Dust exposure, in general population, 871-872
- Early intervention, in chronic obstructive pulmonary disease, 523-547
- Eclampsia, in pregnancy, 1176-1178
- Economic barriers, in cancer screening, 123
- Edema, generalized, in HIV infection, 1438
- Education, as cancer screening barrier, 122-123  
 in pulmonary rehabilitation, for chronic obstructive pulmonary disease, 603
- Electroencephalogram, as screening for obstructive sleep apnea, 809
- Electrolyte disorders, in HIV infection, 1461-1462  
 coincidental, 1443-1444
- Electromyogram, as screening for obstructive sleep apnea, 809
- Electro-oculogram, as screening for obstructive sleep apnea, 809
- Emphysema. See also *Chronic obstructive pulmonary disease (COPD)*.  
 and human immunodeficiency virus, 792-794  
 definition of, 501  
 effect on carbon monoxide uptake, 557-558  
 in alpha<sub>1</sub>-antitrypsin deficiency, 510-511  
 lung reduction surgery for, airway conductance following, 624  
 pressure-volume relationship in, 592  
 surgical options for, 604-605
- Emphysematous tissue, surgical resection of, in chronic obstructive pulmonary disease, 626
- Encephalitis. See also *HIV dementia*.  
 in HIV infection, cytomegalovirus, 1380-1382  
 toxoplasmosis, 1376-1377
- Encephalomyelitis, as paraneoplastic neurologic syndrome, 178
- Encephalopathy, HIV. See *HIV dementia*.
- Endocarditis, in HIV infection, 1503-1504
- Endocrine dysfunction, in children with HIV infection, 1319-1320
- Endocrine paraneoplastic syndrome, 173-177
- Endocrinologic complications, in HIV infection, 1453-1469  
 electrolyte abnormalities, 1443-1444, 1461-1462  
 endocrine pancreas, 1460-1461  
 hypothalamic-pituitary-adrenal axis, 1453-1457  
 hypothalamic-pituitary-gonadal axis, 1459-1460  
 hypothalamic-pituitary-thyroidal axis, 1457-1459  
 wasting syndrome, 1462-1463
- Endometrial cancer, 51-53
- Endometrial hyperplasia, estrogen replacement and, 315
- Endoscopic treatment, of variceal bleeding, 1042-1049
- Endoscopy, for gastroesophageal reflux disease, 418
- Envelope, of human immunodeficiency virus, 1247
- Environmental control, in asthma treatment, 711-713
- Enzyme-linked immunoassay, general concepts concerning, 930-932
- Epilepsy, in preconception counseling, 359-360
- Epworth Sleepiness Scale, 804
- Erythematous lesions, as dermatologic paraneoplastic syndrome, 182-183
- Erythrocytosis, as hematologic paraneoplastic syndrome, 181
- Esophageal acid clearance, in gastroesophageal reflux disease, 416
- Esophageal mucosal injury, in gastroesophageal reflux disease, 417
- Esophageal sphincter, lower, in gastroesophageal reflux disease, 415
- Esophageal stricture, with gastroesophageal reflux disease, primary care management of, 424
- Esophagitis, reflux, definition of, 412  
 primary care management of, 423-424
- Esophagogastric varices, with portal hypertension, 1023
- Esophagus, disorders of, in HIV infection, 1395-1397
- Estrogen replacement, postmenopausal, by primary care physician, 313-317  
 decision concerning, 315-316
- Ethanol, intratumor injection of, for hepatocellular carcinoma, 1135-1136
- Ethical issues, in liver-directed gene therapy, 1208-1210

- Ethics, and managed care, 263-278  
 medical, key principles of, 264-265  
 managed care vs, 271-273  
 traditional values in, 265
- Ethnic background, and genetic screening recommendations, 349
- Ethnic barriers, in cancer screening, 120-122
- Euthyroid sick syndrome, in HIV infection, 1457
- Exercise, and preconception counseling, 352-354
- Exercise endurance, in chronic obstructive pulmonary disease, with oxygen therapy, 595
- Exercise testing, clinical, in chronic airflow limitation, 565-587  
 Borg scale for, 579  
 common measurements during, 575  
 common response patterns, 579  
 conduct of, 574-575  
 criteria for maximal study, 577  
 determinants of, 578  
 end-exercise results, 576-578  
 indications for, 573-574  
 interpretation of, 575-582  
 measurements during, 566  
 ventilatory changes during, 567
- Exercise tolerance, improved, following lung reduction surgery, in chronic obstructive pulmonary disease, 629
- Extrahepatic malignancy, previous, as contraindication to liver transplantation, 1076
- Eye disorders, in HIV infection, 1471-1492
- Familial hypercholesterolemia, liver-directed gene therapy for, 1204-1205
- Family history, in preconception counseling, 348-350
- Fatty liver, acute, of pregnancy, 1174-1176
- Fee-for-service plans, characteristics and typology of, 230-232
- Fenoterol, asthma mortality with, 739  
 for control of bronchial asthma, studies supporting, 725-726
- Fever, in liver transplant recipient, 1110-1112
- Fibrolamellar hepatocellular carcinoma, 918-919
- Financing, at-risk, in managed care, 266
- FK-506, for autoimmune hepatitis, 989
- Fluconazole, for deep fungal infection prophylaxis, in AIDS, 1297-1298
- Focal nodular hyperplasia, hepatic, 910-914
- Folliculitis, in HIV infection, 1427-1428
- Foods, vitamin K content of, 482
- Forced expiratory volume, and lung cancer, 646  
 cigarette smoking and, 504  
 in alpha<sub>1</sub>-antitrypsin deficiency, 510  
 in lung health study, age and gender characteristics, 530  
 symptoms vs, 527  
 with isoproterenol inhalation, 533  
 with methacholine inhalation, 534  
 with coal dust exposure, smoking and, 856-857  
 with grain dust exposure, 864  
 with mineral dust exposure, 862
- Foscarnet, for cytomegalovirus retinitis, 1475-1477
- Fumes, exposure to, and airways obstruction, 867-868  
 in general population, 871-872
- Functional residual capacity, decreased, and hypoxemia during sleep, in chronic obstructive pulmonary disease, 827-828  
 as trigger for increased nocturnal bronchoconstriction, 839
- Fungal infection(s), in HIV infection, 1348-1350  
 chorioretinitis, 1482  
 prophylaxis for, 394-395, 1296
- Galactose oxidase test, as colorectal cancer marker, 187
- Ganciclovir, for cytomegalovirus prophylaxis, in AIDS, 1297  
 for cytomegalovirus retinitis, 1475-1477
- Gas exchange, in chronic airflow limitation, 569-570
- Gases, exposure to, and airways obstruction, 867-868  
 in general population, 871-872
- Gastric antral vascular ectasia, and bleeding, in cirrhotic patient, 1053-1054
- Gastric varices, in chronic liver disease, 1040-1041
- Gastroesophageal reflux disease, 411-429  
 barriers to, defects of, 414  
 continuing primary care management of, 422-426  
 antireflux surgery, 425  
 with Barrett's esophagus, 424-425  
 with esophageal stricture, 424  
 with esophagitis, 423-424  
 with no esophagitis, 425  
 definition of, 411-412  
 delayed gastric emptying in, 416-417  
 extraesophageal manifestations of, 412-414  
 initial evaluation of, 417-419

- Gastroesophageal reflux disease (*Continued*)  
 long-term complications of, 412  
 medications for, rationale of, 419  
 pathophysiology of, 414-417  
 presentation of, 413  
 recommendations for initial therapy, 422  
 treatment of, 419-421  
   H<sub>2</sub> receptor antagonists, 420  
   prokinetic agents, 421  
   proton pump inhibitors, 420-421  
   sucralfate, 421
- Gastrointestinal bleeding, in HIV infection, 1401-1402  
   upper, with chronic liver disease, management of, 1035-1068
- Gastrointestinal manifestations, of HIV infection, 1395-1414  
   abdominal pain, 1397-1398  
     management of, 1400-1401  
   biliary tract disease, 1397-1399  
   bleeding, 1401-1402  
   diarrhea, 1403-1408. *See also Diarrhea.*  
   esophageal symptoms, 1395-1397  
   hepatic disorders, 1402-1403  
   obstruction and perforation, 1400  
   pancreatic disorders, 1400
- GB virus A, B, and C, 950-951
- Gender, and chronic obstructive pulmonary disease, 502
- Gene therapy, liver-directed, 1201-1213.  
   *See also Liver-directed gene therapy.*
- Genetic factors, and chronic obstructive pulmonary disease, 502, 508-512
- Genetic screening, recommendations for, 349
- Glacial acetic acid, exposure to, reactive airways dysfunction syndrome in, 763-764
- Glipizide, for non-insulin-dependent diabetes mellitus, 464
- Glomerular diseases, in HIV infection, 1447
- Glomerulonephritis, interferon therapy in, 962
- Glomerulosclerosis, in HIV infection, 1439
- Glucocorticoid resistance, in HIV infection, 1456
- Glucose, control of, in non-insulin-dependent diabetes mellitus, 458-459  
   fasting plasma, in diabetes mellitus diagnosis, 462
- Glucose tolerance test, oral, for diabetes mellitus diagnosis, 461
- Glyburide, for non-insulin-dependent diabetes mellitus, 464
- Glycogen storage disease, as indication for liver transplantation, 1090
- Gold dust exposure, airway obstruction in, 859-860  
   and chronic obstructive pulmonary disease, 515  
   chronic bronchitis in, 859  
   studies of, 859-860
- Grain dust exposure, airflow obstruction with, 862-865  
   chronic bronchitis with, 863  
   respiratory symptoms with, chances of, 864
- Grain fever, asthma with, 771
- Granulomas, hepatic, and liver function abnormalities, 900-901
- Growth failure, in children with HIV infection, 1319-1320
- Guillain-Barré syndrome, as paraneoplastic neurologic syndrome, 179
- Gynecologic cancer, screening and early diagnosis of, 45-61
- Gynecologic history, in preconception counseling, 344-346
- Gynecology, office, for primary care physician, 299-319, 321-336
- H<sub>2</sub> receptor antagonists, for gastroesophageal reflux disease, 420
- Health care, costs of, in managed care systems, 232-233  
   future quality in, managed care and, 238-239  
   reform of, managed care in, 228
- Health maintenance organizations, characteristics and typology of, 230-232  
   managed care in, 225
- Health Plan Employer Data and Information Set (HEDIS), 248-249
- Heart failure, congestive, warfarin for, primary care physician management of, 479
- Heart rate, as screening for obstructive sleep apnea, 808-809
- Heart valve, prosthetic, warfarin for, primary care physician management of, 478
- HELLP syndrome, in pregnancy, 1178-1179
- Hemangioma, cavernous, hepatic, 907-909  
   case study of, 920-921
- Hematologic disorders, effect on carbon monoxide uptake, 555
- Hematologic manifestations, in children with HIV infection, 1320
- Hematologic paraneoplastic syndrome, 180-181
- Hemobilia, and bleeding, in cirrhotic patient, 1056
- Hemocult test, 29-35. *See also under Stool.*
- Hemochromatosis, and liver function abnormalities, 896

- as indication for liver transplantation, 1089
- genetic, and hepatocellular carcinoma, 1123
- Hemoglobin, effect on carbon monoxide uptake, 554
- glycosylated, for diabetes mellitus diagnosis, 462
- Hemolytic-uremic syndrome, in HIV infection, 1447
- Hemophilus influenzae* pneumonia, in HIV infection, 794
- HemoQuant test, 30. See also under *Stool*.
- Heparin, use in outpatient setting, 487-488
- Hepatic abscess, 913-914
- Hepatic adenoma, 909-910
- Hepatic cavernous hemangioma, 907-909
  - case study of, 920-921
- Hepatic encephalopathy, with portal hypertension, 1028-1030
- Hepatic granulomas, and liver function abnormalities, 900-901
- Hepatic resection, for hepatocellular carcinoma, 1128-1129
- Hepatic rupture, in pregnancy, 1179-1180
- Hepatic solid mass, 907-928
  - benign, 907-910
  - case studies of, 920-923
  - diagnostic evaluation of, 920-923
  - malignant, 914-919
    - hepatocellular carcinoma, 916-919
    - intrahepatic cholangiocarcinoma, 919
    - liver metastases, 914-916
    - case study of, 921-922
- Hepatitis, alcoholic, and liver function abnormalities, 894
- autoimmune, and liver function abnormalities, 896
  - as indication for liver transplantation, 1083
  - characteristics of, 974
  - cholestatic liver disease vs, 1011-1012
  - diagnostic autoantibodies without type specificity, 976-978
  - diagnostic criteria for, 978-982
    - clinical, 978-980
    - differential, 979
    - quantitative, 980-982
  - liver transplantation for, 988-989
  - nonclassic manifestations of, 982-983
    - absence of autoantibodies, 983
    - acute presentation, 982
    - lobular hepatitis, 982-983
    - seropositivity for hepatitis C virus antibodies, 983
  - subclassification of, 973-975
  - treatment of, indications for, 983-984
  - outcomes of, 986-988
  - regimens for, 984-985
    - alternative but unestablished, 989-990
    - variant forms of, 975-976
- in HIV infection, 1402-1403
- ischemic, and liver function abnormalities, 898
- neonatal, treatment of, 1181-1183
- pregnancy in, 1181-1183
- vaccines for, 1189-1200
- viral, serologic diagnosis of, 929-956.
  - See also *Viral hepatitis*.
- Hepatitis A, and liver function abnormalities, 894
  - serologic profile of, 935
  - vaccine for, 1189-1191
- Hepatitis A virus, antibodies to, detection of, 932
  - quantitative tests for, 935
  - serologic diagnosis of, 934-935
- Hepatitis B, and liver function abnormalities, 894-895
  - chronic, as contraindication to liver transplantation, 1074-1075
  - interferon therapy of, 957-963
  - clinical trials of, 957-958
  - dosing and patterns of response to, 959-960
  - patient selection and monitoring, 958-959
  - predictors of response to, 962
  - side effects of, 960-962
  - special patient groups and, 962
  - reactivation of, 940
  - serologic profile of, 938-939
  - therapy of, new classes of drugs, 963
- healthy carrier of, serologic profile of, 938
  - history of, in preconception counseling, 340-341
  - suspected, serologic presentation of, 937
  - vaccine for, 1191-1195
- Hepatitis B core antigen, isolated antibody to, significance of, 940-941
- Hepatitis B virus, antigens and antibodies, 935
  - DNA of, 941
  - in liver transplant recipient, 1111
  - infection with, and hepatocellular carcinoma, 1122-1123
  - serologic diagnosis of, 935-941
  - variants of, 940
- Hepatitis C, acute, diagnosis of, 946-947
  - and liver function abnormalities, 895
- chronic, diagnosis of, 947
  - therapy of, interferon alfa, 963-969
    - improving response rate to, 966-967
    - indications and patterns of response to, 964-966
    - trials of, 964
    - new classes of drugs, 967-968
  - variant presentations of, 968-969



- Hepatitis C (*Continued*)  
 vaccine for, 1195-1196
- Hepatitis C virus, antibodies to, detection of, 931  
 genotypes of, 945-946  
 RNA of, 942-944  
 serologic diagnosis of, 941-947
- Hepatitis D virus, diagnosis of, 947-949  
 IgM antibody to, 948
- Hepatitis E virus, RNA of, 950  
 serologic diagnosis of, 948-950
- Hepatitis G virus, serologic diagnosis of, 951
- Hepatobiliary disease, biochemical abnormalities in, 888
- Hepatocellular carcinoma, 916-919,  
 1121-1145  
 etiology of, 1121-1124  
 aflatoxin B, 1124  
 alcohol, 1124  
 cirrhosis, 1121-1122  
 genetic hemochromatosis, 1123  
 hepatitis infection, 1122-1123  
 metabolic disorders, 1123-1124  
 P53 tumor suppressor gene, 1124  
 prevention of, 1137-1138  
 screening and diagnosis of, 1125-1127  
 alpha-fetoprotein, 1125-1126  
 biopsy, 1127  
 imaging, 1126-1127  
 tumor markers, 1125-1126  
 treatment of, 1127-1137  
 chemotherapy, 1131  
 immunotherapy, 1136-1137  
 molecular approaches to, 1136  
 radiotherapy, 1131, 1134-1136  
 surgical, 1128-1131  
 targeted therapies, 1131-1136  
 embolization and chemoembolization, 1132-1134  
 lipiodol-targeted chemotherapy, 1132-1133  
 radiotherapy, 1134-1136
- Hepatocellular injury, and liver function abnormalities, 893-898
- Hepatocellular necrosis, biochemical abnormalities in, 888
- Hepatorenal syndrome, with portal hypertension, 1028
- Hepatotoxins, occupational and environmental, 892
- Herpes simplex virus, in HIV infection, dermatologic, 1417  
 esophagitis, 1397
- Herpes simplex virus hepatitis, pregnancy in, 1183
- Herpes simplex vulvitis, primary care physician management of, 324
- Herpes zoster, dermatologic, in HIV infection, 1417
- Herpes zoster ophthalmicus, in HIV infection, 1483
- Hiatal hernia, in gastroesophageal reflux disease, 416
- Hispanic-American patients, cancer screening barriers in, 121-122
- Histamine, effect on airway responsiveness, 507
- Histoplasmosis, in HIV infection, 1349  
 dermatologic, 1422-1423
- HIV dementia, 1364-1371  
 clinical features of, 1364-1365  
 diagnostic studies of, 1365  
 mechanisms of, 1369-1370  
 myelopathy in, 1371-1372  
 myopathy in, 1367, 1374-1375  
 pathogenesis of, 1365-1370  
 peripheral neuropathies in, 1367, 1372-1373  
 treatment of, 1370-1371
- HIV infection. See *Human immunodeficiency virus (HIV)*.
- HIV testing, 1289-1292  
 false-positives and negatives in, 1291  
 legal and ethical issues in, 1290-1291  
 patient selection for, 1290  
 problems encountered in, 1291-1292  
 window period in, 1291
- HIV-1-associated cognitive/motor complex. See *HIV dementia*.
- HIV-associated nephropathy (HIVAN), 1437-1439
- Home environment, in preconception counseling, 350
- Home oxygen therapy, 611-622  
 delivery systems for, 614-618  
 oxygen conserving devices, 616-617  
 physician prescription of, 618  
 portable/ambulatory, 615-616  
 stationary, 614-615  
 transtracheal, 617-618  
 for chronic obstructive pulmonary disease, 593-598  
 administration devices, 596-598  
 delivery systems, 596  
 effects of, 594-596  
 long-term, indications for and appropriate use of, 611-614  
 medical considerations in, 612-614  
 reimbursement for, 612  
 prescription of, physician responsibility in, 618-620
- Honesty, in managed care, ethical conflict in, 272
- Hospital(s), in managed care system, future implications for, 237-238
- Hospital care, dimensions of quality of, 252  
 U.S. Healthcare performance report for, 253

- Human immunodeficiency virus (HIV),  
 1239-1261  
 asthma and, 790-791  
 bronchial hyperreactivity and, 790-791  
 bronchiectasis and, 791-793  
 bullous lung disease and, 792-794  
 chronic bronchitis and, 791-792  
 emphysema and, 792-794  
 epidemiology of, 1223-1238, 1284-1289  
   age, 1228  
   deaths from, 1224-1225  
   gender, 1225-1228  
   geographic trends, 1232  
   global trends, 1234-1235  
   in women, 1225-1228  
   molecular, 1235-1236  
   overall morbidity and mortality, 1224  
   prevention of, 1236  
   racial and ethnic minorities, 1228-1229  
   revised case definition, impact of, 1232-1234  
 risk behavior, 1229-1232  
   heterosexual transmission, 1231  
   injecting drug use, 1230-1231  
   men having sex with men, 1229-1230  
 infection with, 1283-1307  
   acute renal failure in, 1444-1448  
   cardiac involvement in, 1493-1512. See also *Cardiac involvement*.  
   classification of, 1286  
   complications of, evolution of, 1285  
   definition of, 1285-1287  
   dermatologic complications of, 1415-1435. See also *Dermatologic complications*.  
   development of AIDS in, 1287-1289  
   diagnosis of, 1289-1292  
   endocrinologic complications of, 1453-1469. See also *Endocrinologic complications*.  
   gastrointestinal manifestations of, 1395-1414. See also under *Gastrointestinal*.  
   medical management in, 1292-1301  
   antiretroviral therapy, 1298-1301  
   initial evaluation, 1293-1295  
   prevention of opportunistic infections, 1295-1298  
   neurologic manifestations of, 1363-1494. See also *Nervous system; Neurologic manifestations*.  
   ophthalmic complications of, 1471-1492. See also *Ophthalmic complications*.  
   opportunistic infections in, prophylaxis for, 388-395, 1355  
   pediatric, 1309-1336. See also *Children*.  
   prevalence of, 1284-1285  
   preventing transmission of, 1301-1302  
   primary care of, 375-409  
   pulmonary disease in, 1337-1362. See also *Pulmonary disease*.  
   renal complications in, 1437-1451. See also under *Renal*.  
   risk for, 1290  
   obstructive lung diseases and, 790-795  
   particles of, 1245-1253  
     envelope, 1247  
     proteins, 1248-1250  
     RNA, 1247  
     subtypes (clades or subgroups) of, 1250-1253  
   pathogenesis of, 1253-1255  
   preconception counseling in, 341-342  
   primary care of, 375-409  
     antiretrovirals, 383-387  
     branched-chain DNA analyses, 387-388  
   initial evaluation, 376-383  
     laboratory analyses, 381-382  
     office visit, 376-377  
     referrals, 382-383  
     screening for anal disease, 378-379  
     screening for cervical disease, 377-378  
   tuberculosis skin testing/prophylaxis, 379-380  
   vaccines, 380-381  
   interventions by CD4 counts, 384  
   model for managed care, 397-399  
   opportunistic infection prophylaxis in, 388-395, 1379  
   polymerase chain reaction analyses, 387-388  
   prevention of wasting, 396-397  
   pulmonary function tests and, 794-795  
   replication cycle of, points of antiviral inhibition in, 1264  
   retroviral taxonomy, 1240-1243  
   strains of, pathogenesis of, 1253  
 Human immunodeficiency virus-1 (HIV-1), drug resistance of, 1253  
 epidemics of, 1252  
 infection with, defects in host defenses associated with, 1288  
   outcome of, 1254  
 phylogenetic tree of, 1251  
 replication cycle of, 1241-1245  
 structural gene expression of, 1245  
 structural proteins of, 1247  
 virion structure of, 1246  
 worldwide geographic distribution of, 1251  
 Human immunodeficiency virus-2 (HIV-2), worldwide geographic distribution of, 1251  
 Hyperbilirubinemia, unconjugated, and liver function abnormalities, 901-902  
 Hypercalcemia, as paraneoplastic endocrine syndrome, 174-176

- Hypercholesterolemia, familial, liver-directed gene therapy for, 1204-1205
- Hyperemesis gravidarum, in pregnancy, 1170-1171
- Hyperinflation, in chronic obstructive pulmonary disease, 591-592
- Hyperlipidemia, in liver transplant recipient, 1106-1107
- Hypertension, chronic, in preconception counseling, 355-356
- portal, 1021-1034. See also *Portal hypertension*.
- with continuous positive airway pressure, in obstructive sleep apnea, 814
- Hyperthyroidism, in HIV infection, 1458
- Hypnogram tracings, overnight, in chronic obstructive pulmonary disease, 835
- Hypnotics, for hypoxemia during sleep, in chronic obstructive pulmonary disease, 832
- Hypoalbuminemia, in HIV infection, 1438
- Hypocalcemia, coincidental, in HIV infection, 1443
- Hypoglycemia, in HIV infection, 1461
- Hypogonadism, in HIV infection, 1459-1460
- Hypokalemia, coincidental, in HIV infection, 1443
- Hypomagnesemia, coincidental, in HIV infection, 1443
- Hyponatremia, coincidental, in HIV infection, 1441-1443
- Hypotension, in severe acute asthma, 695
- Hypothalamic-pituitary-adrenal axis, complications in, in HIV infection, 1453-1457
- Hypothalamic-pituitary-gonadal axis, complications in, in HIV infection, 1459-1460
- Hypothalamic-pituitary-thyroidal axis, complications in, in HIV infection, 1457-1459
- Hypothyroidism, in HIV infection, 1458
- Hypouricemia, coincidental, in HIV infection, 1443
- Hypoventilation, during sleep, in chronic obstructive pulmonary disease, 826-827
- Hypoxemia, during sleep, in chronic obstructive pulmonary disease, 825-828
- acetazolamide for, 831
- alcohol for, 832
- almitrine for, 830
- consequences of, 828
- continuous positive airway pressure for, 833
- hypnotics for, 832
- oxygen therapy for, 829-830
- progestogens for, 830-831
- protriptyline for, 831-832
- theophylline for, 832
- ventilation augmentation for, 833-834
- in cystic fibrosis, 822-823
- in chronic airflow limitation, 569
- Ichthyosis, in HIV infection, 1427
- Imaging, in hepatocellular carcinoma screening and diagnosis, 1126-1127
- Immunization(s), history of, in preconception counseling, 346-347
- in children with HIV infection, 1326
- in liver transplant recipient, 1105
- Immunocytochemistry, for poorly differentiated neoplasms, 157
- Immunoglobulin, intravenous, for autoimmune hepatitis, 989-990
- Immunosuppression, in liver transplant recipient, 1108-1110
- adverse effects of, 1109
- Immunotherapy, for hepatocellular carcinoma, 1136-1137
- Inappropriate antidiuretic hormone secretion, syndrome of, as paraneoplastic endocrine syndrome, 176-177
- Indinavir, for HIV infection, 1273-1274
- recommended dosing of, 1265
- Infection history, in preconception counseling, 339-344
- Infestations, dermatologic, in HIV infection, 1423-1424
- Infiltrative disorders, and liver function abnormalities, 900
- Inflammation, and asthma worsening at night, 837-838
- chronic, in reactive airways dysfunction syndrome, 756
- in nonalcoholic steatohepatitis, 1151
- Inflammation-modifying mediators, impaired release of, with long-term beta-agonist use, 737
- Inflammatory demyelinating polyneuropathy, acute, as paraneoplastic neurologic syndrome, 179
- Inflammatory disorders, dermatologic, in HIV infection, 1428-1429
- Informed consent, in managed care, ethical conflict in, 272
- Inguinal lymph nodes, in metastases of unknown primary site, treatment of, 165-166
- Inspiratory/expiratory timing, in mechanical ventilatory support of severe acute asthma, 691
- Institutional barriers, in cancer screening, 126-129

- Insulin, for non-insulin-dependent diabetes mellitus, 465-466
- Intention-to-treat analysis, of smoking intervention program, 537-541
- Interferon, for chronic hepatitis B, 957-958  
dosing and patterns of response to, 959-960  
in special patient groups, 962  
indications and contraindications, 958  
predictors of response to, 962  
side effects of, 960-962
- Interferon alfa, for chronic hepatitis C,  
improving response rate to, 966-967  
indications and patterns of response to, 964-966  
trials of, 964
- Intermittent mandatory ventilation, in mechanical ventilatory support of severe acute asthma, 692
- International Autoimmune Hepatitis Group, diagnostic criteria of, 980-981
- Intrahepatic cholangiocarcinoma, 919
- Intrauterine device, for contraception by primary care physician, 310
- IPPB trial, background factors in, 646
- Ipratropium, for control of bronchial asthma, studies supporting, 725-726
- Ischemic hepatitis, and liver function abnormalities, 898
- Isoniazid, for tuberculosis prophylaxis, in AIDS, 1297
- Isoprenaline, asthma mortality with, 739
- Isoproterenol inhalation, forced expiratory volume with, in lung health study, 533
- Isosporiasis, and diarrhea, in HIV infection, 1406
- Jaundice, history of, in liver function evaluation, 889  
in liver transplant recipient, 1112-1113
- Johns Hopkins Lung Project, background factors in, 646
- Justice, as medical ethical principle, 264
- Kaposi's sarcoma, in AIDS, 1289  
in HIV infection, cardiac, 1502  
dermatologic, 1419, 1429-1431  
eye, 1483-1484  
pulmonary, 1351-1353
- Keratoacanthoma, skin cancer screening of, 108-109
- Kidney. See under *Renal*.
- Lactic acidosis, coincidental, in HIV infection, 1443
- Lambert-Eaton myasthenic syndrome, as paraneoplastic neurologic syndrome, 179-180
- Lamivudine, for HIV infection, 386, 1271, 1299  
in children, 1324  
recommended dosing of, 1265
- Laser lung reduction, in chronic obstructive pulmonary disease, 626
- Left ventricular function, with continuous positive airway pressure, in obstructive sleep apnea, 814-815
- Lentigo maligna, skin cancer screening of, 109-110
- Leucovorin, for *Pneumocystis carinii* pneumonia, 783-784
- Leukocytosis, as hematologic paraneoplastic syndrome, 180-181
- Leukoencephalopathy, progressive  
multifocal, in HIV infection, 1366, 1368  
central nervous system, 1379-1380
- Leukoplakia, oral hairy, in HIV infection, 1418
- Levonorgestrel, contraception by primary care physician, 313
- Limb muscles, in chronic airflow limitation, 573
- Lipiodol radiotherapy, for hepatocellular carcinoma, 1134-1135
- Lipiodol-targeted chemotherapy, for hepatocellular carcinoma, 1132-1133
- Liposomes, liver-directed gene therapy with, 1204
- Liver. See also under *Hepatic*.  
biopsy of, for nonalcoholic steatohepatitis, 1149  
disease of. See *Liver disease*.  
focal fatty infiltration of, 912-913  
focal nodular hyperplasia of, 910-914  
malignancy of, as indication for liver transplantation, 1085-1088  
liver-directed gene therapy for, 1207-1208  
recurrence following liver transplantation, 1086  
solid mass of, evaluation of, 907-928.  
See also *Hepatic solid mass*.  
transplantation of, 1069-1102, 1103-1120.  
See also *Liver transplantation*.
- Liver cytosol type 1, antibodies to, in autoimmune hepatitis, 977-978
- Liver disease, acute failure, as indication for liver transplantation, 1080-1082  
alcoholic, as indication for liver transplantation, 1084-1085  
autoimmune, 973-994  
cholestatic, 995-1019  
approach to patient with, 1013-1014  
differential diagnosis of, 996, 1008-1012

Liver disease (*Continued*)

- chronic, pregnancy in, 1180-1184
    - upper gastrointestinal bleeding with, **1035-1068**
      - causes of, 1040
      - laboratory data for, 1037-1038
      - physical examination for, 1037
      - prognostic indicators of, 1036-1037
      - radiologic studies of, 1038
  - in pregnancy, **1167-1187**. See also *Pregnancy*.
  - metastases, 914-916
    - case study of, 921-922
    - recurrence of, in liver transplant recipient, 1114-1115
  - Liver function tests, abnormal, nonhepatic causes of, 888
    - abnormalities in, drug-induced, 891
    - elevated results in, in liver transplant recipient, 1112-1113
    - in pregnancy, 1178-1179
    - evaluation of, history and physical examination, 889-893
    - results in, evaluation of, **887-906**
  - Liver/pancreas, antibodies to, in autoimmune hepatitis, 977-978
  - Liver tests, abnormal, in HIV infection, 1403
  - Liver transplantation, **1069-1102**
    - contraindications to, absolute, 1072-1074
    - relative, 1074-1078
    - indications for, disease-specific, 1080-1088
      - acute liver failure, 1080-1082
      - alcoholic liver disease, 1084-1085
      - autoimmune hepatitis, 988-989, 1083
      - chronic viral hepatitis, 1084
      - cryptogenic cirrhosis, 1082
      - hepatic malignancy, 1085-1088
      - hepatocellular carcinoma, 1129-1131
      - portal hypertension, 1030-1031
      - primary biliary cirrhosis, 1000-1001, 1082-1083
      - primary sclerosing cholangitis, 1007, 1083
    - general, 1070-1072
    - uncommon, 1088-1091
  - recipient of, long-term management of, **1103-1120**
    - alcohol recidivism, 1114-1115
    - depression and other neuropsychiatric problems, 1115-1116
    - diabetes mellitus, 1113
    - drug interactions, 1112, 1116
    - fever, 1110-1112
    - general preventive medicine, 1104-1108
      - antibiotic prophylaxis, 1108
      - hyperlipidemia, 1106-1107
      - immunizations, 1105
      - malignancy screening, 1105-1106
      - nutritional issues, 1107
    - immunosuppression, 1108-1110
    - jaundice and elevated liver function tests, 1112-1113
    - liver disease recurrence, 1114-1115
    - renal dysfunction, 1114
    - survival with and without, 1079
    - timing of, 1078-1080
- Liver-directed gene therapy, **1201-1213**
  - candidate diseases for, 1204-1208
  - familial hypercholesterolemia, 1204-1205
  - liver cancer, 1207-1208
  - metabolic disorders, 1206-1207
  - ornithine transcarbamylase deficiency, 1205-1206
  - viral hepatitis, 1207
- ethical issues in, 1208-1210
- gene transfer technology, 1201-1204
- adeno-associated virus, 1203-1204
- adenovirus, 1202-1203
- liposomes, 1204
- retrovirus, 1202
- Lower extremity exercise, for chronic obstructive pulmonary disease, 601-602
- Lung(s), AIDS and, **775-801**
- elastic recoil of, following lung reduction surgery, 630, 634
  - function of, with regular vs oral beta-agonists, 729-732
  - overdistention of, in mechanical ventilatory support of severe acute asthma, 690
- Lung cancer, advice to clinicians about, 652-654
- algorithm for, 205
  - and age, 647
  - and chronic obstructive pulmonary disease, **645-655**
    - case-finding approach to, 649
  - cell types in, 66
  - detection tools for, 67-70
  - diagnosis of, 204-207, 653
  - disease in, 66-67
  - early detection in, **63-82**
    - discussion of, 75-77
    - Mayo Lung Project, 73-75
    - programs for, 75-77
    - studies of, 71-73
  - in high-risk patients, diagnostic approach to, 651
  - overdiagnosis of, 75
  - populations at risk, 65-66
  - preoperative lung function in, 651
  - radiation therapy for, survival in, 650
  - risk of, algorithm for, 653
  - roentgenographically occult, location and staging of, 652

- scope of problem, 65
- screening for, 648-651
  - case finding vs, 64
  - radiologic, 202
- smoking and, 645, 647
- stages of, 649
- surgical therapy for, survival in, 650
- treatment of, 70
- Lung disease, infiltrative, effect on carbon monoxide uptake, 555
- obstructive, and HIV infection, 790-795
- and sleep, 821-850
- preexisting, and lung cancer, 66
- Lung health study, airway responsiveness in, 541-542
- annual visit follow-up rates in, 529
- average cigarette consumption in, 529
- chronic wheezing in, 532
- deaths within five years, 648
- methacholine response in, 542
- participants in, 545-547
- population for, characteristics of, 526-530
- smoking intervention program in, 530-535. See also *Smoking intervention program*.
- symptoms vs lung function in, 527
- wheezing with cold in, 531
- Lung reduction surgery, in chronic obstructive pulmonary disease, 623-643
  - advanced techniques in, 626-628
  - conductance vs total lung capacity in, 631
  - future directions in, 640-641
  - historical background of, 623-625
  - mortality in, 635
  - new approaches to, 625-628
  - patient selection for, 638-639
  - physiologic basis for, 628-634
    - airflow, 628-632
    - cardiovascular function, 633-634
    - lung elastic recoil, 628-632
    - respiratory muscles, 632-633
  - pulmonary function testing, 625-626
  - rehabilitation following, 640-641
  - results to date, 635-636
  - static transpulmonary pressure vs total lung capacity in, 630
  - understanding pathology and pathophysiology in, 625
- Lung transplantation, alpha<sub>1</sub>-antitrypsin replacement therapy after, 667-668
- in chronic airflow limitation, 657-670
  - annual activity in, 659
  - choice of procedure for, 663-664
  - complications in, 668
  - criteria for, 660-661
  - current activity in, 658-659
  - history of, 657-658
  - improved exercise tolerance following, 666-667
  - improved lung function following, 666-667
  - indications for, 659
  - lung function before and after, 663
  - recipient selection in, 660-661
  - results with, 664-667
  - single vs bilateral, 657-658, 664
  - survival following, 662, 665
  - timing of, 661-663
- Lymph nodes, cancer of, with unknown primary site, 165-166
- Lymphocytic myocarditis, in HIV infection, 1497
- Lymphoma, in HIV infection, cardiac, 1502-1503
  - central nervous system, 1377-1379
  - dermatologic, 1431
  - non-Hodgkin's, 1352
- Lymphoreticular system, infection of, in HIV infection, 1369
- Macrovascular disease, diabetic, detection and intervention in, 469-470
- Magnesium sulfate, for severe acute asthma, 687
- Malignancy, humoral hypercalcemia of, as paraneoplastic endocrine syndrome, 175-176
  - screening for, in liver transplant recipient, 1105-1106
- Malignant melanoma, skin cancer
  - screening of, 110-112
- Mallory-Weiss tear, and bleeding, in cirrhotic patient, 1054-1055
- Malnutrition, as contraindication to liver transplantation, 1078
- Mammography, screening, 15, 202
  - benefits of, 17-18
  - compliance with, 20-21
  - guidelines for, 17
  - history of, 16
  - new modalities for, 18
- Managed care, accountability in, 245-261
  - definition of, 246
  - ethical assumptions of, 267-268
  - ethical principles vs, 271-273
  - ethics and, 263-278
  - in HIV patient, model for, 397-399
  - in practice management, 286
  - limitations on care, 269-271
  - moral/ethical questions concerning, 276
  - opposition to, 275
  - past, present, and future, 225-240
    - future, 235-242
    - frontiers of, 240-242
    - implications for hospitals, 237-238

Managed care (*Continued*)

- implications for physicians, 235-237
- quality in, 238-239
- trends and changes in, 239-240
- past, 226-227
- present, 227-238
  - characteristics and typology of, 230-232
    - health care costs in, 232-233
    - medical education in, 233-235
    - physicians and, 227-230
    - quality of care in, 232
- physician in, 245-261
  - accountability of, 254-257
  - principal features of, 265-267
  - proposals for reform in, 273-277
  - quality in, 247-251
  - suggestions for clinicians in, 273-277
  - systems of, characteristics and typology of, 230-232
- Mandibular osteotomy, for obstructive sleep apnea, 812
- Marketing, in practice management, 286
- Maternal age, in preconception counseling, 338-339
- Matrix dot blot immunoassay, of hepatitis C virus, 942
- Maximal ventilatory capacity, in chronic airflow limitation, 568
- Mayo Lung Project, for lung cancer early detection, 73-75
- Medical care, cost-effectiveness of, 255
- Medical education, in managed care systems, 233-235
- Medical history, in preconception counseling, 339-344
- Medical illness, chronic, in preconception counseling, 354-365
  - asthma, 354-355
  - autoimmune disorders, 363-364
  - cardiac disease, 361-363
  - chronic hypertension, 355-356
  - diabetes mellitus, 356-357
  - phenylketonuria, 364-365
  - renal disease, 361
  - seizure disorders, 359-360
  - thromboembolic disease, 357-359
  - urinary tract infection, 361
- Medical office design, in practice management, 280-281
- Medical records, in practice management, 283-284
- Medical treatment, of severe acute asthma, 684-688
- Medication(s), and asthma, environmental control of, 713
  - for obstructive sleep apnea, 811
- Medication history, in preconception counseling, 347-348
- Medicine, computers and, 287-296. *See also Computers.*
- Medroxyprogesterone acetate, contraception by primary care physician, 312
- Melanoma, skin cancer screening of, 109-110
- Memorial Sloan-Kettering Cancer Center-Strang Clinical Trial, 32, 34
- Meningitis, cryptococcal, in HIV infection, 1382-1383
- Menstruation, disorders of, primary care physician management of, 325-330
- Metabolic acidosis, in chronic airflow limitation, 571-572, 580
- Metabolic disorders, and hepatocellular carcinoma, 1123-1124
  - as indication for liver transplantation, 1088
  - liver-directed gene therapy for, 1206-1207
- Metabolic rate, in chronic airflow limitation, 572
- Metastases, of unknown primary site, 153-171
  - clinical manifestations of, 154-155
  - diagnostic evaluation of, 155-159
  - clinical investigations, 158-159
  - histologic diagnosis, 156
  - pathology, 156-158
  - major sites of tumor involvement in, 155
  - recommended evaluation and therapy for, 161
  - treatment of, 159-167
    - empiric, 166-167
    - favorable clinical subgroups, 160-166
      - axillary nodal, 162-163
      - cervical lymph node squamous cancer, 165
      - increased prostate specific antigen, 163
      - inguinal lymph nodes, 165
      - men with skeletal metastases, 163
      - neuroendocrine tumors, 164-165
      - poorly differentiated (adeno)carcinoma, 163-164
      - women with peritoneal carcinomatosis, 160-162
- Metformin, for non-insulin-dependent diabetes mellitus, 464-465
- Methacholine, effect on airway responsiveness, 506
  - response to, in lung health study, 531, 534, 542
- Microsporidiosis, and diarrhea, in HIV infection, 1406-1407
- Midlevel providers, and cancer screening, 135-144
  - collaborative practice with, issues related to, 138



- definition of, 135-138
- effectiveness of, 137-138
- Mineral dust exposure, chronic airflow obstruction in, studies of, 852-862
- Molecular approaches, to hepatocellular carcinoma, 1136
- Molecular biology diagnostic techniques, 932-934
- Molluscum contagiosum, dermatologic, in HIV infection, 1418-1419
- Monoamine oxidase inhibitors, for depression, 441-442
- Mononeuropathy multiplex, in HIV infection, 1367, 1373
- Mucin-like carcinoma associated antigen, as breast cancer marker, 193-194
- Myasthenic syndrome, Lambert-Eaton, as paraneoplastic neurologic syndrome, 179-180
- Mycobacterial disease, in HIV infection,
  - choroiditis, 1482-1483
  - dermatologic, 1420
  - pulmonary, 1346-1348
- Mycobacterium avium* complex, in children with HIV infection, 1319
  - prophylaxis for, in AIDS, 1296-1297
  - in HIV infection, 393-394
- Myelopathy, in HIV dementia, 1371-1372
- Myocardial disease, in HIV infection, 1494-1500
  - noninflammatory necrosis, 1498
- Myocarditis, in HIV infection, 1496-1499
- Myoclonus, as paraneoplastic neurologic syndrome, 178
- Myopathy, in HIV infection, 1367, 1374-1375
  - in mechanical ventilatory support of severe acute asthma, 691
- Nasal/oral airflow, as screening for obstructive sleep apnea, 809
- Nedocromil, for asthma, 705, 714
- Nefazodone, for depression, 442
- Neoplasms, in HIV infection, cardiac, 1503-1503
  - dermatologic, 1429-1431
  - pulmonary, 1351-1354
- Nephropathy, diabetic, detection and intervention in, 467-468
  - HIV-associated, 1437-1441
- Nephrotic syndrome, in HIV infection, 1438
- Nephrotoxicity, with foscarnet, 1476
- Nervous system, central, HIV-associated disorders of, primary, 1364-1375
  - HIV dementia, 1364-1371. See also *HIV dementia*.
  - secondary, 1376-1380
  - lymphoma, 1366, 1377-1379
  - progressive multifocal leukoencephalopathy, 1379-1380
  - toxoplasmosis, 1376-1377
- infections of, in HIV infection, 1380-1383
  - cryptococcal meningitis, 1382-1383
  - cytomegalovirus, 1380-1382
  - syphilis, 1383
- Neuroendocrine tumors, poorly differentiated, in metastases of unknown primary site, 164-165
- Neurologic manifestations, of HIV infection, **1363-1494**
  - in children, 1320-1324
  - major, 1366-1367
  - mechanisms of, 1369-1370
- Neurologic paraneoplastic syndrome, 177-180
- Neuro-ophthalmic lesions, in HIV infection, 1484-1485
- Neuropathy, diabetic, detection and intervention in, 468-469
  - sensory, subacute, as paraneoplastic neurologic syndrome, 179
- Neuropsychiatric problems, in liver transplant recipient, 1115-1116
- Neuropsychologic function, in obstructive sleep apnea, effect of continuous positive airway pressure on, 815-816
- Neurosyphilis, in HIV infection, 1367
- Nevi, atypical, skin cancer screening of, 111
- Nicotine gum use, in smoking intervention program, 533-534
- Nitrogen dioxide levels, and chronic obstructive pulmonary disease, 516
- Nocturnal Oxygen Therapy Trial, 612
- Non-Hodgkin's lymphoma, in HIV infection, 1351-1352
  - central nervous system, 1379
- Nonalcoholic steatohepatitis, **1147-1166**. See also *Steatohepatitis*.
- Nonendocrine tumors, liver metastases from, 915-916
- Nonmaleficence, as medical ethical principle, 264
- Nonnucleoside reverse transcriptase inhibitors, for HIV infection, 1271-1272
- Nucleoside analogue reverse transcriptase inhibitors, for HIV infection, 1265-1271, 1298
- Nurse-midwives, certified, qualifications of, 136-137
- Nurse practitioners, qualifications of, 136
- Nutrition, in liver transplant recipient, 1107

Nutrition (*Continued*)

- in preconception counseling, 354
- Nutritional deficiency, and myocardium, in HIV infection, 1499-1500
- Obesity, severe, as contraindication to liver transplantation, 1077-1078
- Obstetric history, in preconception counseling, 345-346
- Obstetrics/gynecology performance report, 256
- Obstructive lung disease, and sleep, 821-850
- Obstructive sleep apnea, 803-820. See also *Sleep apnea*.
- Occupational asthma, nonsensitizing causes of, 749-774. See also *Asthma*.
- Occupational exposures, and chronic obstructive pulmonary disease, 502, 514-515
  - in preconception counseling, 350-351
- Octreotide, for variceal bleeding, 1051
- Ocular infections, in HIV infection,
  - opportunistic, 1473-1483
  - syphilis, 1482
  - toxoplasmosis, 1481-1482
- Ocular lesions, drug-induced, in HIV infection, 1484-1485
- Ocular neoplasms, in HIV infection, 1483-1484
- Office gynecology, for primary care physician, 299-319, 321-336
- Ophthalmic complications, of HIV infection, 1471-1492
  - drug-induced ocular lesions, 1484-1485
  - neuro-ophthalmic lesions, 1484-1485
  - ocular neoplasms, 1483-1484
  - opportunistic ocular infections, 1473-1483
  - retinopathy, 1471-1473
- Opportunistic infections, in HIV infection,
  - prevention of, 1295-1298
  - prophylaxis for, 388-395
- Opsoclonus myoclonus, as paraneoplastic neurologic syndrome, 178
- Oral contraceptive pills, for contraception by primary care physician, 310-312
- Organic dust exposure, chronic airflow obstruction in, studies of, 862-867
- Organic dust toxic syndrome, asthma with, 771
- Ornithine transcarbamylase deficiency, liver-directed gene therapy for, 1205-1206
- Osteolytic hypercalcemia, local, as paraneoplastic endocrine syndrome, 176
- Osteoporosis, postmenopausal estrogen replacement for, 315
- Outcomes, focus on, in managed care, 267
- measurement of, in practice management, 284-285
- Ovarian cancer, 54-58
  - diagnosis of, 54-58
  - CA-125 antigen, 55-56
  - imaging studies, 56
  - radiologic imaging, 211-212
  - ultrasonography, 56-58
  - epidemiology of, 54
  - screening recommendations for, 58
  - tumor markers for, 195-196
- Oximetry, as screening for obstructive sleep apnea, 808-809
- Oxygen, during sleep, for cystic fibrosis, 823-824
  - for hypoxemia in chronic obstructive pulmonary disease, 829-830
  - for severe acute asthma, 685
  - home, 611-622. See also *Home oxygen therapy*.
- Oxygen desaturation, in chronic airflow limitation, 569
- Oxygen saturation, overnight, in chronic obstructive pulmonary disease, 835
- P53 tumor suppressor gene, and hepatocellular carcinoma, 1124
- Pain, pelvic, primary care physician management of, 321-323
- Pancreas, disorders of, in HIV infection, 1400
  - endocrine, complications in, in HIV infection, 1460-1461
- Pancreatic cancer, algorithm for, 213
  - computed tomography of, 214
  - diagnostic radiologic imaging of, 212-215
  - endoscopic retrograde cholangiopancreatography of, 215
  - transhepatic cholangiography of, 215
  - tumor markers for, 190-191
  - ultrasonography of, 214
- Papanicolaou smear, 47-50
  - abnormal, follow-up of, 48-50
  - Bethesda system for, 48-49
  - by primary care physician, 303-307
  - reporting of, 48
- Papilledema, with cryptococcal meningitis, in AIDS, 1485
- Papillomavirus, human, dermatologic, in HIV infection, 1418
- Papulosquamous disease, dermatologic, in HIV infection, 1424-1428
- Paracentesis, large-volume, for ascites, 1026

- Paraneoplastic syndrome(s), 173-184  
 dermatologic, 181-183  
   acanthosis nigricans, 182  
   erythematous lesions, 182-183  
   Sweet's syndrome, 183  
   tripe palms, 182  
 endocrine, 173-177  
   ectopic Cushing's syndrome, 174-175  
   hypercalcemia, 174-176  
   syndrome of inappropriate secretion of antidiuretic hormone, 176-177  
 hematologic, 180-181  
   anemia, 181  
   coagulation disorders, 181  
   leukocytosis, 180-181  
   thrombocytopenia, 181  
   thrombocytosis, 181  
 neurologic, 177-180  
   acute inflammatory demyelinating polyneuropathy, 179  
   cancer-associated retinopathy, 178  
   cerebellar degeneration, 177-178  
   encephalomyelitis, 178  
   Guillain-Barré syndrome, 179  
   Lambert-Eaton myasthenic syndrome, 179-180  
   opsoclonus myoclonus, 178  
   polymyositis/dermatomyositis, 180  
   spinal cord involvement, 179  
   subacute sensory neuropathy, 179  
 Patient barriers, in cancer screening, 117-123  
   cancer knowledge, attitudes, and beliefs, 119-120  
   economic, 123  
   ethnic, racial, and cultural, 120-122  
   nonadherence to recommendations, 117-119  
   perceived susceptibility, 119  
   physician-patient relationship, 119  
   sociodemographic, 122-123  
 Patient education, in asthma treatment, 706-711  
   action plan for, 711-712  
   early recognition of exacerbations, 709  
   goals of treatment, 708-709  
   home monitoring of peak expiratory flow, 710-711  
   methods for, 711  
   technical aspects of medications, 707-708  
   treatment of exacerbations, 709-710  
   understanding asthma, 707  
   understanding medications, 707  
 Payer demands, in managed care, 267  
 Peak expiratory flow, changes in, with regular vs as-needed beta-agonists, 730  
 Pelvic pain, primary care physician management of, 321-323  
 Pentamidine, aerosolized, for *Pneumocystis carinii* pneumonia, in HIV patient, 390-391  
   prophylaxis, 1295-1296  
 Pentamidine isethionate, for *Pneumocystis carinii* pneumonia, 783-784  
 Peptic ulcer disease, and bleeding, in cirrhotic patient, 1055-1056  
 Pericardial disease, in HIV infection, 1504  
 Peritoneal carcinomatosis in women, treatment of, 160-162  
 Peritoneovenous shunt, for ascites, 1026  
 Peritonitis, spontaneous bacterial, with portal hypertension, 1027-1028  
 Personnel, in practice management, 287  
 Pharmacologic agents, for variceal bleeding, 1050-1051  
 Pharmacologic therapy, in mechanical ventilatory support of severe acute asthma, 692  
 Phenylketonuria, in preconception counseling, 364-365  
 Phosphatidylcholine, polyunsaturated, for autoimmune hepatitis, 989  
 Photosensitivity reactions, dermatologic, in HIV infection, 1429  
 Physician(s), evaluation of, fairness of comparisons, 258-260  
   in managed care, 227-230, **245-261**  
   future implications for, 235-237  
   individual accountability of, 254-257  
   primary care. See *Primary care physician*.  
   proposed role of, 276  
   resource allocation by, ethics of, 274  
   responsibility of, in home oxygen therapy prescription, 618-620  
 Physician assistants, qualifications of, 137  
 Physician-patient relationship, as cancer screening barrier, 119  
   in managed care, 272-273  
*Pityrosporum* infections, dermatologic, in HIV infection, 1421-1422  
 Placental alkaline phosphatase, as testicular cancer marker, 192  
 Platelet count, low, in pregnancy, 1178-1179  
*Pneumocystis carinii* choroiditis, in HIV infection, 1483  
*Pneumocystis carinii* pneumonia, in AIDS, 776-786  
   adjunctive corticosteroids for, 785-786  
   chest radiograph in, 778-780  
   clinical presentation of, 777-781  
   diagnosis of, 781-783  
   epidemiology of, 776-777  
   high-resolution computed tomography of, 781  
   treatment of, 783-785  
   in HIV infection, 1340-1344  
   diagnosis of, 1343

- Pneumocystis carinii* pneumonia (Continued)  
 in children, 1315  
 prophylaxis and treatment of, 389-391  
 prophylaxis for, 1295-1297, 1341  
 radiographic appearance of, 1342  
 risk of, 1341  
 treatment of, 1344
- Pneumonia, bacterial, in AIDS, 786-790  
 chest radiographs of, 789  
 clinical presentation of, 788  
 diagnosis of, 788-790  
 epidemiology of, 786-788  
 treatment of, 790  
 in HIV infection, 1345-1346
- Hemophilus influenzae*, in HIV infection, 794
- Pneumocystis carinii*, in AIDS, 776-786.  
 See also *Pneumocystis carinii* pneumonia.
- Pseudomonas aeruginosa*, in AIDS, 789
- Streptococcus pneumoniae*, in AIDS, 789
- Pneumonitis, interstitial, in HIV infection, 1354, 1366
- Pneumothorax, in severe acute asthma, 695  
 tension, in *Pneumocystis carinii* pneumonia, 780
- Point-of-service plans, characteristics and typology of, 230-232
- Polymerase chain reaction, in serologic diagnosis, 934
- Polymyositis, as paraneoplastic neurologic syndrome, 180
- Polyneuropathy(ies), inflammatory  
 demyelinating, as paraneoplastic neurologic syndrome, 179  
 in HIV dementia, 1367, 1373
- Polyradiculopathy, progressive, in HIV dementia, 1373
- Polysomnography, for obstructive sleep apnea, 806-807
- Portal hypertension, 1021-1034  
 complications of, 1023-1031  
 ascites, 1023-1026  
 esophagogastric varices, 1023  
 hepatic encephalopathy, 1028-1030  
 hepatorenal syndrome, 1028  
 liver transplantation, 1030-1031  
 spontaneous bacterial peritonitis, 1027-1028  
 gastropathy of, and bleeding, in cirrhotic patient, 1054  
 pathophysiology of, 1022-1023
- Portosystemic shunt, improper placement of, 1077
- intrahepatic, transjugular, for ascites, 1026  
 for variceal bleeding, 1051  
 prior, as contraindication to liver transplantation, 1076-1077
- Positive end-expiratory pressure, effect on inspiratory effort, 693
- Postmenopausal estrogen replacement, by primary care physician, 313-317
- Potassium regulation, abnormalities of, in HIV infection, 1461-1462
- Potroom asthma, 771
- Practice management, 279-287  
 computer systems for, 288-290  
 guidelines for, 267  
 managed care, 286  
 marketing, 286  
 medical office design, 280-281  
 medical records, 283-284  
 personnel, 287  
 practice policies, 282-283  
 preventive health and outcomes measurement, 284-285  
 reimbursement, 285-286  
 scheduling, 281-282  
 telephone management, 282
- Preconception counseling, by primary care physician, 337-373  
 chronic medical illness, 354-365  
 asthma, 354-355  
 autoimmune disorders, 363-364  
 cardiac disease, 361-363  
 diabetes mellitus, 356-357  
 hypertension, 355-356  
 phenylketonuria, 364-365  
 renal disease, 361  
 seizure disorders, 359-361  
 thromboembolic disease, 357-359  
 family history, 348-350  
 hepatitis B, 340-341  
 history for, 371  
 HIV infection, 341-342  
 immunization history, 346-347  
 interventions for, 372  
 laboratory evaluation for, 372  
 medication history, 347-348  
 risk assessment, 371  
 sexually transmitted diseases, 344-345  
 social history, 350-354  
 toxoplasmosis, 342-343  
 tuberculosis, 343  
 varicella, 344
- Predictive value, disease prevalence and, 5-6
- Prednisolone, for HIV infection, 1301
- Prednisone, for autoimmune hepatitis, 984
- Preeclampsia, in pregnancy, 1176-1178
- Preferred provider organizations, characteristics and typology of, 230-232
- Pregnancy, intrahepatic cholestasis of, cholestatic liver disease vs, 1009  
 liver disease in, 1167-1187  
 approach to patient with abnormal liver function tests, 1167-1170

- diagnostic tests, 1169
- differential diagnosis, 1170
- history, 1167-1168
- physical examination, 1169
- liver disorders specific to, 1170-1180
- acute fatty liver of pregnancy, 1174-1176
- clinical characteristics of, 1171
- HELLP syndrome, 1178-1179
- hepatic rupture, 1179-1180
- hyperemesis gravidarum, 1170-1171
- preeclampsia/eclampsia, 1176-1178
- mortality risk associated with, 363
- normal, liver function test results in, 1168
- risk classification of, 348
- Premenstrual syndrome, primary care physician management of, 330-332
- Pressure support ventilation, in mechanical ventilatory support of severe acute asthma, 692
- Prevention, definitions for, 2
- Preventive health, in practice management, 284-285
- Preventive medicine, in liver transplant recipient, 1104-1108
- Primary care physician, office gynecology for, 299-319, 321-336
  - breast diseases, 332-333
  - contraception, 307-313
  - menstrual disorders, 325-330
  - Papanicolaou smear, 303-307
  - pelvic pain, 321-323
  - postmenopausal estrogen replacement, 313-317
  - premenstrual syndrome, 330-332
  - vaginitis, 299-303
  - vulvar disease, 332-335
- outpatient anticoagulation issues for, 475-491
- preconception counseling by, 337-373
- Progestogens, for hypoxemia during sleep, in chronic obstructive pulmonary disease, 830-831
- Prokinetic agents, for gastroesophageal reflux disease, 421
- Prostate cancer, algorithm for, 211
- curability of, 85
- detection of, 85
- diagnostic radiologic imaging of, 209-211
- epidemiology of, 83-84
- genetic factors in, 84
- incidence of, 84-85
- mortality in, 85
- screening for, 83-98
  - and improved treatment outcomes, 92-93
  - realities of, 93-94
  - tests for, 86-92
- digital rectal examination, 86-88
- prostate specific antigen, 88-92
- transrectal ultrasound, 88
- tumor markers of, 188-190
- Prostate specific antigen, as prostate cancer marker, 189
  - for prostate cancer screening, 88-92
  - increased, with metastases of unknown primary site, 163
- Prostatic acid phosphatase, as prostate cancer marker, 189
- Protein(s), of human immunodeficiency virus, 1248-1250
- Proteinuria, in HIV infection, 1438
- Proton pump inhibitors, for gastroesophageal reflux disease, 420-421
- Protriptyline, for hypoxemia during sleep, in chronic obstructive pulmonary disease, 831-832
- Pseudomonas aeruginosa* pneumonia, in AIDS, 789
- Psoriasis, in HIV infection, 1425-1426
- Psychological support, in pulmonary rehabilitation, for chronic obstructive pulmonary disease, 603-604
- Psychosocial impact, in children with HIV infection, 1326
- Pulmonary circulation, alterations in, effect on carbon monoxide uptake, 555
- Pulmonary disease, chronic obstructive. See *Chronic obstructive pulmonary disease (COPD)*.
  - in HIV infection, 1337-1362
    - approach to, 1339-1340
    - noninfectious problems, 1351-1354
    - interstitial pneumonitis, 1354
    - neoplasms, 1351-1354
    - prophylaxis for, 1340, 1355
    - radiographic patterns of, 1340-1342
    - spectrum of, 1337-1339
- Pulmonary function, decline in, with airway hyperresponsiveness, 507
  - in obstructive sleep apnea, effect of continuous positive airway pressure on, 816
  - testing of, for lung reduction surgery, in chronic obstructive pulmonary disease, 625-626
  - tests of, and human immunodeficiency virus, 794-795
  - for severe acute asthma, 680-681
- Pulmonary function tests, in patients with *Pneumocystis carinii* pneumonia, 1343
- Pulmonary infections, in HIV infection, 1340-1351
  - bacterial, 1344-1346
  - fungal, 1348-1350
  - mycobacterial, 1346-1348
  - Pneumocystis carinii* pneumonia, 1340-1344

- Pulmonary infections (*Continued*)  
 viral, 1349-1351
- Pulmonary rehabilitation, for chronic obstructive pulmonary disease, 601-604
- Pulmonary resection, for lung cancer, 70
- Purple toes syndrome, with warfarin, 486
- Purpura, thrombotic thrombocytopenic, in HIV infection, 1447
- Pyogenic hepatic abscess, 913
- Pyridoxine, for tuberculosis prophylaxis, in AIDS, 1297
- Pyrimethamine, for toxoplasmosis encephalitis, in HIV infection, 1377
- Quality of care, dimensions of, 251
- in managed care systems, 232
- Quality of life, and liver transplantation, 1071
- Racial barriers, in cancer screening, 120-122
- Radioactive microspheres, for hepatocellular carcinoma, 1134
- Radiographic/radionuclide studies, in diagnosis of metastases of unknown primary site, 158
- Radioimmunoassay, general concepts concerning, 930-932
- Radiologic imaging, in cancer, 201-218
- in cancer diagnosis, 203-215
- breast, 203-204
- colorectal, 207-209
- lung, 204-207
- ovarian, 211-212
- pancreatic, 211-212
- prostate, 209-211
- in cancer screening, 201-203
- Radiotherapy, for hepatocellular carcinoma, 1131, 1134
- Rapamycin, for autoimmune hepatitis, 990
- Reactive airways dysfunction syndrome, 750-770
- clinical manifestations of, 751-752
- effect of corticosteroids on, 759
- epidemiologic surveys of, 759-770
- review of publications, 762-770
- functional sequelae in, 757-758
- histologic lesions following exposure, time course of, 755
- pathologic features, 752-756
- pathophysiologic hypothesis of, 756-757
- prevalence and historical aspects of, 750-751
- with chronic low-level exposure to irritants, 768-769
- with exposure to high irritant concentration, 763-765
- Recombinant immunoblot assay, of hepatitis C virus, 942-944
- Reflux esophagitis, definition of, 412
- Reimbursement, in practice management, 285-286
- Reiter's syndrome, dermatologic, in HIV infection, 1426-1427
- Rejection, in liver transplant recipient, 1109
- Renal allograft, recipients of, preconception guidelines for, 362
- Renal allograft recipients, preconception guidelines for, 362
- Renal complications, in HIV disease, 1437-1451
- coincidental, 1441-1444
- Renal disease, chronic, in preconception counseling, 361
- primary unrelated, in HIV infection, 1448
- Renal dysfunction, in liver transplant recipient, 1114
- Renal failure, acute, and HIV infection, 1444-1448
- drug-induced, in HIV infection, 1446
- in HIV vs non-HIV patients, 1446
- as contraindication to liver transplantation, 1077
- Renal replacement therapy, HIV infection during, 1448
- Renal ultrastructural changes, in HIV infection, 1439
- Residence, as cancer screening barrier, 122-123
- Respiration, normal, during sleep, 821-822
- Respiratory efforts, as screening for obstructive sleep apnea, 809
- Respiratory failure, in severe acute asthma, 695
- Respiratory illnesses, in children with HIV infection, 1317
- Respiratory infections, and chronic obstructive pulmonary disease, 502, 512-514
- Respiratory muscles, function of, in chronic airflow limitation, 570-571
- in chronic obstructive pulmonary disease, 592-593
- lung reduction surgery and, 632-633
- Retinitis, cytomegalovirus, in HIV infection, 1473-1580
- diagnosis of, 1475
- intravitreal therapy for, 1478
- prevention of, 1479
- relapse in, 1477
- retinal detachment with, 1479
- varicella zoster, in HIV infection, 1480-1481

- Retinopathy, cancer-associated, as  
paraneoplastic neurologic syndrome,  
178  
diabetic, detection and intervention in,  
466-467  
in: HIV infection, 1471-1473
- Retroviruses, liver-directed gene therapy  
with, 1202  
old classification of, 1241  
taxonomy and characteristics of, 1242-  
1243
- Rifabutin, for *Mycobacterium avium*  
complex prophylaxis, in AIDS, 1297
- Risk pooling, in managed care, 267
- Risk reduction, in cancer screening, 9-10
- Ritonavir, for HIV infection, 1273  
recommended dosing of, 1265
- RNA, of human immunodeficiency virus,  
1247
- Rubella immunization, history of, in  
preconception counseling, 347
- Salbutamol, for control of bronchial  
asthma, studies supporting, 723-727
- Salmeterol, for control of bronchial  
asthma, studies supporting, 727
- Saquinavir, for HIV infection, 1272-1273,  
1299  
recommended dosing of, 1265
- Sarcoidosis, cholestatic liver disease vs,  
1011
- Scabies infestations, dermatologic, in HIV  
infection, 1423-1424
- Scheduling, in practice management,  
281-282
- Sclerosing cholangitis, primary, 1002-1008  
and liver function abnormalities, 900  
as indication for liver transplantation,  
1083  
biopsy of, 1006  
cholangiogram of, 1005  
clinical presentation of, 1003  
complications of, 1007-1008  
diagnosis of, 1004-1006  
epidemiology of, 1003  
liver transplantation for, 1007  
pathogenesis of, 1003  
prognosis of, 1008  
radiologic and histologic features of,  
1004  
symptoms and signs at diagnosis,  
1004  
treatment of, 1006  
secondary, cholestatic liver disease vs,  
1011
- Sclerotherapy, for variceal bleeding,  
1042-1044
- Seborrheic keratosis, skin cancer screening  
of, 108-109
- Seizure disorders, in preconception  
counseling, 359-360
- Sensitivity, in cancer screening, 5
- Sensitizing agents, in asthma,  
environmental control of, 711-713
- Sensory neuropathy, subacute, as  
paraneoplastic neurologic syndrome,  
179
- Serologic assays, general concepts  
concerning, 930-932
- Serologic diagnosis, of viral hepatitis,  
929-956. See also *Viral hepatitis*.
- Serotonin reuptake inhibitors, selective, for  
depression, 441
- Serum acid phosphatase, as prostate  
cancer marker, 190
- Serum tumor markers, in diagnosis of  
metastases of unknown primary site,  
159
- Sexual history, in liver function  
evaluation, 892
- Sexually transmitted diseases, history of,  
in preconception counseling, 344-345
- Sigmoid colon, carcinoma of, radiologic  
imaging of, 210
- Sigmoidoscopy, for occult blood in stool,  
35-37
- Sinusitis, in HIV infection, 1345
- Skeletal metastases, of unknown primary  
site, in men, 163
- Skin cancer, early treatment of, 100-101  
morbidity/mortality of, 99-101  
natural history of, 100  
prevalence of, 99-100  
screening for, 99-114  
actinic (solar) keratosis, 105  
agents for, 102-104  
basal cell carcinoma, 106  
benign lentigo, 109  
effectiveness of, 101-102  
keratoacanthoma, 108-109  
lentigo maligna, 109-110  
malignant melanoma, 110-112  
melanoma, 109-110  
methods of, 101  
nevi, 111  
objectives of, 99-102  
seborrheic keratosis, 108-109  
squamous cell carcinoma, 107-108  
target population for, 104-105
- Skin necrosis, with warfarin, 486
- Sleep, as trigger for increased nocturnal  
bronchoconstriction, 838  
asthma and, 834-841. See also *Asthma*.  
normal respiration during, 821-822  
obstructive lung disease and, 821-850
- Sleep apnea, obstructive, 803-820  
as trigger for increased nocturnal  
bronchoconstriction, 839  
clinical features of, 804-806



Sleep apnea (*Continued*)

- clinical predictors of, 807-808
- differential diagnosis of, 805
- monitoring equipment for, practice parameters for, 809-810
- pathophysiologic consequences of, 814-816
- polysomnography for, 806-807
- screening techniques for, 808-810
- treatment of, 810-813
  - general measures, 810-811
  - indication for, 810
  - specific, 811-813
    - dental appliances, 813
    - medications, 811
    - nasal continuous positive airway pressure, 813
    - surgery, 811-813
- Sleepiness, daytime, with sleep apnea, 805
- Smoking, and lung cancer, 65, 645, 647
  - cessation of, 530-541. *See also Smoking intervention program.*
  - improved forced expiratory volume with, 540
  - preditors of, 536
  - weight gain with, 536
- in preconception counseling, 351
- passive exposure to, and chronic obstructive pulmonary disease, 502, 517-518
- Smoking intervention program, deaths in, 538
  - design and results of, 530-535
    - behavioral interview, 531
    - extended intervention, 534
    - group intervention, 532-533
    - maintenance, 534-535
    - nicotine gum use, 533-534
    - orientation, 531-532
    - physician message, 530-531
  - effectiveness of, 535-536
  - forced expiratory volume in, changes in, 538
    - postbronchodilator, 539, 540, 541
    - prebronchodilator, 539
  - inhaler compliance results in, 537
  - intention-to-treat analysis of, 537-541
- Snoring, as screening for obstructive sleep apnea, 807-808
- Social history, in preconception counseling, 350-354
  - alcohol, 351-352
  - exercise, 352-354
  - home environment, 350
  - illicit drug use, 352
  - nutrition, 354
  - occupational/toxic exposures, 350-351
  - smoking, 351
- Sociodemographic barriers, in cancer screening, 122-123

- Sodium balance, abnormalities of, in HIV infection, 1461
- Sodium cromoglycate, for asthma, 705, 714
- Solar keratosis, skin cancer screening of, 105
- Somatostatin, for variceal bleeding, 1050
- Specificity, in cancer screening, 5
- Spermicides, contraception by primary care physician, 307-310
- Spinal cord, disorders of, as paraneoplastic neurologic syndrome, 179
- Sputum evaluation, for lung cancer detection, 69-70
- Squamous carcinoma, metastatic, of unknown primary site, recommended evaluation and therapy for, 161
- skin cancer screening of, 107-108
- Standard of care, definition of, 269-270
- Status asthmaticus, definition of, 677
- Stavudine, for HIV infection, 386, 1270-1271, 1299
  - recommended dosing of, 1265
- Steatohepatitis, nonalcoholic, 1147-1166
  - and liver function abnormalities, 897-898
  - causes of, 1148
  - clinical manifestations of, 1151-1155
    - imaging, 1153-1155
    - laboratory evaluation, 1152-1153
    - physical findings, 1152
    - recommended evaluation, 1155
    - symptoms, 1151
  - diagnosis of, 1147-1151
  - histologic findings in, 1150
  - natural history of, 1155-1156
  - pathophysiology of, 1158-1161
  - patient characteristics in, 1156-1158
  - risk factors for, 1156-1158
  - treatment of, 1161-1162
- Steatosis, hepatic, clinical manifestations of, 1151-1155
  - natural history of, 1155-1156
  - pathophysiology of, 1158-1161
    - causes, 1158-1160
    - end-stage liver disease, 1160-1161
    - fibrogenesis, 1160-1161
    - inflammation, 1160
    - treatment of, 1161-1162
- Stereoisomerism, and airway hyperresponsiveness, with long-term beta-agonist use, 736-738
- Sterilization, contraception by primary care physician, 313
- Stool, occult blood in, tests for, 29-35
  - artifactual results from, 30
  - colonoscopy, 37-38
  - Danish study, 33-35
  - discussion of, 38-39
  - immunochemical, 31
  - Memorial Sloan-Kettering Cancer Center-Strang Clinical Trial, 32, 34

- Norwegian study, 33-34  
 randomized trials of, 34  
 sigmoidoscopy, 35-37  
 Swedish study, 32-34  
 University of Minnesota Colon  
 Cancer Control Study, 31-32, 34
- Streptococcus pneumoniae* pneumonia, in  
 AIDS, 789
- Sucralfate, for gastroesophageal reflux  
 disease, 421
- Suicide, depression and, 448-449
- Surgery, for obstructive sleep apnea,  
 811-813
- Sweet's syndrome, as dermatologic  
 paraneoplastic syndrome, 183
- Syphilis, in HIV infection, central nervous  
 system, 1383  
 ocular, 1482
- T-Ag antigen, as colorectal cancer marker,  
 187
- T helper lymphocytes, counts of, in  
 children with HIV infection, and  
 antiretroviral therapy initiation, 1325  
 depletion of, and AIDS, 1288
- Tachyarrhythmias, in severe acute asthma,  
 695
- Tachyphylaxis, with long-term beta-  
 agonist use, 733
- Tacrolimus, in liver transplant recipient,  
 1108
- Tamponade, mechanical, for variceal  
 bleeding, 1049-1050
- Targeted therapies, for hepatocellular  
 carcinoma, 1131-1136
- Team care, in managed care, 266
- Telephone management, in practice  
 management, 282
- Terbutaline, for control of bronchial  
 asthma, studies supporting, 723-726
- Testicular cancer, tumor markers for,  
 191-193  
 alpha-fetoprotein, 192  
 beta-human chorionic gonadotropin,  
 192  
 placental alkaline phosphatase, 192
- Testosterone level, in HIV infection, 1459
- Theophylline, during sleep, for cystic  
 fibrosis, 824  
 for asthma, 686, 704  
 for chronic obstructive pulmonary dis-  
 ease, 599-600  
 for control of bronchial asthma, studies  
 supporting, 724  
 for hypoxemia during sleep, in chronic  
 obstructive pulmonary disease, 832  
 in cystic fibrosis, 824
- Thrombocytopenia, as hematologic  
 paraneoplastic syndrome, 181
- Thrombocytosis, as hematologic  
 paraneoplastic syndrome, 181
- Thromboembolic disease, in preconception  
 counseling, 357-359
- Thrombotic thrombocytopenic purpura, in  
 HIV infection, 1447
- Thymic hormone extracts, for autoimmune  
 hepatitis, 990
- Tidal volume, in mechanical ventilatory  
 support of severe acute asthma, 691
- Tolazamide, for non-insulin-dependent  
 diabetes mellitus, 464
- Tolbutamide, for non-insulin-dependent  
 diabetes mellitus, 464
- Toxic exposures, in preconception  
 counseling, 350-351
- Toxoplasmosis, history of, in  
 preconception counseling, 342-343  
 in HIV infection, 1351, 1376-1377  
 encephalitis, 1366  
 ocular, 1481-1482  
 prophylaxis for, 391-392, 1296
- Tracheal noise, as screening for obstructive  
 sleep apnea, 809
- Tracheostomy, for obstructive sleep apnea,  
 812
- Transjugular intrahepatic portosystemic  
 shunt (TIPS), for ascites, 1026  
 for variceal bleeding, 1051  
 improper placement of, 1077
- Transrectal ultrasound, for prostate cancer  
 screening, 88
- Trazodone, for depression, 442
- Trichomoniasis, primary care physician  
 treatment of, 302
- Tricyclic antidepressants, for depression,  
 439-441
- Trimethoprim-sulfamethoxazole, for  
*Pneumocystis carinii* pneumonia,  
 783-784, 786, 1344  
 for prophylaxis, 1295-1296  
 in HIV patient, 390
- Trimetrexate, for *Pneumocystis carinii*  
 pneumonia, 783-785
- Tripe palms, as dermatologic  
 paraneoplastic syndrome, 182
- Tuberculosis, history of, in preconception  
 counseling, 343  
 prophylaxis for, in AIDS, 1296-1297  
 pulmonary, in HIV infection, 1346-1348  
 skin testing/prophylaxis of, in HIV pa-  
 tient, 379-380
- Tubular necrosis, acute, in HIV infection,  
 1444-1445
- Tumor(s), and bleeding, in cirrhotic  
 patient, 1057
- Tumor markers, 185-199  
 for breast cancer, 193-195  
 for colorectal cancer, 186-188  
 for ovarian cancer, 195-196

- Tumor markers (*Continued*)  
 for pancreatic cancer, 190-191  
 for prostate cancer, 188-190  
 for testicular cancer, 191-193  
 in hepatocellular carcinoma screening and diagnosis, 1125-1126
- Tumor suppressor gene, and hepatocellular carcinoma, 1124
- Unconventional therapy, in severe acute asthma, 694
- University of Minnesota Colon Cancer Control Study, 31-32, 34
- Upper extremity exercise, for chronic obstructive pulmonary disease, 602-603
- Upper gastrointestinal bleeding, with chronic liver disease, management of, 1035-1068. See also *Variceal bleeding*.
- Urinary tract infection, in preconception counseling, 361
- Ursodeoxycholic acid, for autoimmune hepatitis, 989
- U.S. Healthcare performance reports, 257
- Uterine bleeding, abnormal, primary care physician management of, 326-328
- Uvulopalato(pharyngo)plasty, for obstructive sleep apnea, 812
- Vaccinations, in children with HIV infection, 1326
- Vaccines, hepatitis, 1189-1200. See also under *Hepatitis*.  
 in HIV patient, 380-381
- Vacuolar myelopathy, in HIV infection, 1366, 1371
- Vaginal bleeding, abnormal, 326-327
- Vaginal candidiasis, primary care physician treatment of, 300-301
- Vaginal neoplasia, follow-up of, 50
- Vaginitis, primary care physician treatment of, 299-303
- Vaginosis, bacterial, primary care physician treatment of, 301-302
- Valsalva maneuver, effect on carbon monoxide uptake, 554
- Variceal bleeding, 1035-1068  
 diagnostic evaluation of, 1039  
 economic impact of, 1039-1040  
 endoscopic treatment of, 1042-1049  
 adjunctive therapy, 1048-1049  
 combination, 1046-1048  
 cyanoacrylate, 1048  
 failure of, 1049  
 injection sclerotherapy, 1042-1043  
 results of, 1044-1045  
 variceal ligation, 1045-1046  
 nonendoscopic treatment of, 1049-1053  
 mechanical tamponade, 1049-1050  
 pharmacologic agents, 1050-1051  
 radiologic modalities, 1051-1052  
 surgery, 1052-1053
- Varicella, history of, in preconception counseling, 344
- Varicella zoster retinitis, in HIV infection, 1480-1481
- Vascular lesions, myocardial, in HIV infection, 1498
- Vasculitis, drug-induced, in HIV infection, 1498-1499
- Vasopressin, for variceal bleeding, 1050
- Venlafaxine, for depression, 442-443
- Venous thromboembolic disease, warfarin for, primary care physician management of, 477-478
- Ventilation, augmentation of, for hypoxemia during sleep, in chronic obstructive pulmonary disease, 833-834  
 control of, in chronic obstructive pulmonary disease, 592  
 dyssynchrony of, in mechanical ventilatory support of severe acute asthma, 690-691  
 in chronic airflow limitation, 566-568  
 intermittent positive-pressure, during sleep, for cystic fibrosis, 825
- Ventilatory support, mechanical, in severe acute asthma, 688-694  
 alternatives to, 694  
 complications of, 690-691  
 gas exchange goals, 689-690  
 partial, 692-693  
 pharmacologic therapy in, 693-694  
 total, 691-692
- Viral attachment inhibitors, for antiretroviral therapy, 1263-1265
- Viral disease, in HIV infection, dermatologic, 1416-1419  
 infections, 1349-1351  
 myocarditis, 1496
- Viral hepatitis, 957-972  
 cholestatic liver disease vs, 1012  
 chronic, as indication for liver transplantation, 1084  
 detection of antigen of, 933  
 history of, 929-930  
 liver-directed gene therapy for, 1207  
 pregnancy in, 1181-1183  
 serologic diagnosis of, 929-956
- Vitamin K, interaction with warfarin, 480-482
- Vulvar disease, primary care physician management of, 323-325
- Vulvar neoplasia, follow-up of, 50

- Warfarin, complications of, 483-487
  - interactions with, 480-483
  - primary care physician management of, dosing and monitoring, 479-483
    - for atrial fibrillation, 476-477
    - for congestive heart failure, 479
    - for coronary artery disease, 478-479
    - for prosthetic heart valve, 478
    - for venous thromboembolic disease, 477-478
  - sample schedule for, 481
  - therapeutic ranges for, 476
- Wasting syndrome, in AIDS, 1286-1287
  - in HIV infection, 1462-1463
- Wheezing, in alpha<sub>1</sub>-antitrypsin deficiency, 509
- WHO system, of cervical cytology nomenclature, 305
- Wilson's disease, and liver function abnormalities, 896-897
  - as indication for liver transplantation, 1088-1089
- Wrist activity, as screening for obstructive sleep apnea, 809
- Zalcitabine, for HIV infection, 385-386, 1269-1270, 1299
  - recommended dosing of, 1265
- Zidovudine, for HIV dementia, 1370
  - for HIV infection, 383-385, 1266-1267, 1298-1299
    - in children, 1324
    - myopathy in, 1375
  - recommended dosing of, 1265